Parkinson Disease · Web of Medicine

On this page

Quick Reference

RxDrug of choiceCarbidopa-Levodopa (25/100 mg)

AltAlternativesMAO-B inhibitors (Rasagiline), Dopamine agonists (Pramipexole), COMT inhibitors (Entacapone)

⊘AvoidTypical antipsychotics (Haloperidol), Metoclopramide, Prochlorperazine

DxTest of choiceClinical diagnosis (supported by αSyn-SAA or DaTscan)

ScKey scoreMDS-UPDRS (Motor), Hoehn & Yahr (Staging)

→When to referAtypical features (red flags), refractory motor fluctuations, or consideration for DBS

PD is a clinical diagnosis based on bradykinesia and levodopa responsiveness; management must be multidisciplinary, addressing both motor and non-motor complications early.

Parkinson disease (PD) is a chronic, progressive neurodegenerative disorder characterized by the selective loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of misfolded α-synuclein aggregates known as Lewy bodies. It is the fastest-growing cause of neurological disability globally, with a clinical presentation traditionally defined by the motor triad of bradykinesia, resting tremor, and rigidity. However, the modern understanding of PD has shifted toward a biological framework (SynNeurGe) that recognizes a prolonged prodromal phase involving non-motor symptoms like hyposmia and REM sleep behavior disorder. Management requires a dynamic, multidisciplinary approach focusing on dopaminergic replacement, surgical interventions like Deep Brain Stimulation (DBS), and intensive physical and respiratory rehabilitation to mitigate complications such as falls and aspiration pneumonia.

Overview and Recommendations

Background

•Recognize Parkinson disease (PD) as a multisystem alpha-synucleinopathy characterized by the progressive loss of dopaminergic neurons, leading to both classic motor deficits and a wide array of non-motor symptoms (NMS).
•Identify the clinical phases of the disease, starting with a prodromal phase (hyposmia, constipation, REM sleep behavior disorder) that can precede motor onset by decades, followed by early-stage responsiveness to therapy and late-stage motor complications like (FOG).
•Understand the shifting diagnostic paradigm toward the SynNeurGe framework, which classifies the disease based on α-synuclein (S), neurodegeneration (N), and genetics (G) rather than purely clinical phenomenology.
•Note the demographic trends where PD disproportionately affects males (2:1 ratio) and is increasingly prevalent in aging populations, though early-onset Parkinson disease (EOPD) affects those aged 21–50 and often carries a higher genetic burden.
•Distinguish idiopathic PD from 'Parkinson-plus' syndromes such as (MSA) and (PSP), which typically present with more rapid progression and poor levodopa response.

Evaluation

•Suspect PD in any patient presenting with asymmetric motor signs, particularly a 4–6 Hz 'pill-rolling' rest tremor, lead-pipe or cogwheel rigidity, or unexplained slowness in activities of daily living.
•Confirm the presence of bradykinesia, the essential motor sign, by observing a decrement in amplitude or speed during repetitive movements such as finger tapping or rapid alternating hand movements.
•Perform a Levodopa Challenge by administering a suprathreshold dose (typically 200 mg of levodopa) and measuring the MDS-UPDRS Part III score; a >30% improvement in motor function strongly supports an idiopathic PD diagnosis.
•Identify 'red flags' that suggest alternative diagnoses, including early severe autonomic failure (orthostatic hypotension), vertical supranuclear gaze palsy, or falls occurring within the first three years of symptom onset.
•Screen for non-motor features during the clinical encounter, specifically asking about hyposmia (loss of smell), REM sleep behavior disorder (acting out dreams), and chronic constipation.
•Order a structural MRI to rule out secondary causes such as normal pressure hydrocephalus or vascular , though conventional imaging is often normal in early idiopathic PD.
•Utilize DaTscan ([123I]FP-CIT SPECT) in cases of clinical uncertainty to visualize striatal dopamine transporter density and confirm a presynaptic dopaminergic deficit.
•Consider a skin biopsy to detect S129 phospho-α-synuclein (pαSyn) at the C7 and Th12 dermatomes, which can highly accurately differentiate synucleinopathies from tauopathies like PSP.
•Assess gait and balance using dual-task challenges (e.g., walking while performing mental arithmetic) to reveal impaired motor automaticity and the risk of .
•Monitor orthostatic blood pressure trajectories longitudinally, as early autonomic failure is a marker for faster disease progression and increased vascular risk.
•Evaluate for impulse control disorders (ICD) such as pathological gambling or hypersexuality, particularly in patients already receiving dopamine agonist therapy.

Management

•Administer Carbidopa-Levodopa (e.g., 25/100 mg TID) as the gold standard for motor symptom control, ensuring strict adherence to dosing schedules to avoid 'off' periods.
•Prioritize medication timing in hospitalized patients; delays or omissions of dopaminergic doses are associated with increased morbidity and mortality in the inpatient setting.
•Manage 'wearing-off' fluctuations by adding adjunctive therapies such as COMT inhibitors, MAO-B inhibitors, or Amantadine-IR 200 mg/day to reduce peak-dose dyskinesia.
•Prescribe a cycling exercise protocol (40-60 minutes, 3 times per week) to improve movement vigor and significantly reduce the progression of urinary frequency.
•Implement High-Intensity Expiratory Muscle Strength Training (EMST) at 60% of maximal expiratory pressure to improve swallowing safety and prevent .
•Refer for bilateral subthalamic nucleus (STN) (DBS) in patients with advanced PD who experience medication-refractory motor fluctuations but remain levodopa-responsive.
•Utilize non-invasive neuromodulation such as transcutaneous auricular vagus nerve stimulation (taVNS) to improve gait parameters and sleep quality.
•Treat mild-to-moderate depressive symptoms with High-Definition Transcranial Direct Current Stimulation (HD-tDCS) targeting the left dorsolateral prefrontal cortex.
•Address postural deformities like camptocormia using wearable sensor-based braces that provide vibratory feedback when forward flexion exceeds a pre-set threshold.
•Manage chronic constipation using the '6S' model, emphasizing high fiber intake and standardized laxative protocols.
•Screen for and manage bone health by performing a baseline DXA scan at diagnosis and initiating Vitamin D and Calcium supplementation to prevent fragility fractures.
•Avoid typical antipsychotics (e.g., Haloperidol) and certain antiemetics (e.g., Metoclopramide) as they can severely exacerbate parkinsonian motor symptoms.
•Consider Donor (dFMT) in drug-naïve patients to improve both motor and gastrointestinal symptoms via the gut-brain axis.
•Transition to Continuous Subcutaneous Apomorphine Infusion (CSAI) in advanced stages if the oral route is compromised by severe or terminal illness.
•Provide genetic counseling for patients with GBA1 or LRRK2 variants, focusing on variable penetrance and the implications for family members.

Board Review — High Yield

•Lewy Bodies — Pathognomonic intracellular aggregates of misfolded alpha-synuclein.
•Bradykinesia — The essential clinical feature required for diagnosis; characterized by slowness and decrement in amplitude.
•RBD (REM Sleep Behavior Disorder) — A highly specific prodromal marker for future synucleinopathy development.
•GBA1 Mutation — The most common genetic risk factor for Parkinson disease.
•Micrographia — A classic clinical sign where handwriting becomes progressively smaller and cramped.
•Pill-rolling tremor — A 4–6 Hz resting tremor that typically disappears with purposeful movement.
•Honeymoon Period — The initial years of treatment where patients have a robust and stable response to levodopa.
•Freezing of Gait — An episodic 'glued to the floor' sensation, often triggered by doorways or turning.

Deep Dive — Evidence Details

Definition, Synonyms, and Classification

▸Parkinson's disease is increasingly defined biologically as Neuronal α-Synuclein Disease (NSD) based on n-asyn biomarkers [200].
▸The NSD-ISS framework stages PD from Stage 0 (at risk) to Stage 6 (severe impairment) [200].
▸PD is a primary alpha-synucleinopathy, sharing pathological features with DLB and MSA [4, 196].
▸Motor asymmetry is a defining clinical characteristic used to track disease progression and treatment response [29].
▸Cognitive impairment in PD is classified into Level I (screening) and Level II (comprehensive) diagnostic tiers [197, 202].
▸Surveillance definitions often rely on a combination of ICD codes and specific medication use, such as levodopa or amantadine [7, 195, 203].

Dx Diagnostic Essentials: The alpha-synuclein Seed Amplification Assay (αSyn-SAA) in CSF is a critical tool for confirming Lewy body pathology in clinical routine, showing high sensitivity for PD [27].

CP Clinical Pearl: Motor asymmetry (the difference between left and right limb scores) is a key diagnostic feature of PD, though its magnitude may fluctuate following advanced therapies like STN-DBS [29].

! Warning: Amantadine, used for PD motor symptoms, is associated with a risk of corneal edema, which requires prompt recognition to prevent permanent ocular damage [203].

Definition and Core Characteristics

Parkinson's disease (PD) is a progressive neurodegenerative disorder primarily characterized by motor phenomenology, though it is increasingly recognized as a multisystem condition with extensive non-motor manifestations ^[2]^[5]. Traditionally, the diagnosis relies on the presence of motor symptoms, but recent advancements have shifted the definition toward a biological framework. The Neuronal α-Synuclein Disease (NSD) definition has been proposed, which identifies the disease by the presence of an in vivo biomarker of neuronal alpha-synuclein (n-asyn) pathology ^[200]. This biological definition allows for staging across a continuum (Stages 0 to 6) based on n-asyn biomarkers, dopaminergic dysfunction, and clinical severity ^[200].

Synonyms and Related Terms

PD is frequently referred to as idiopathic Parkinson's disease to distinguish it from secondary forms of parkinsonism ^[6]^[195]. In the context of its underlying pathology, it is classified as an alpha-synucleinopathy, a group of disorders that also includes Dementia with Lewy Bodies (DLB), Multiple System Atrophy (MSA), and Pure Autonomic Failure (PAF) ^[4]^[196]^C. When PD is identified in its earliest stages before the onset of classic motor symptoms, it is termed prodromal Parkinson's disease ^[196]^C^[200].

Classification and Staging Systems

Classification of PD is multifaceted, involving clinical, biological, and functional criteria:

The NSD Integrated Staging System (NSD-ISS): This research framework stages the disease from Stage 0 (genetic risk without pathology) to Stage 6 (severe functional impairment) ^[200]. Stages 1 and 2 represent preclinical and prodromal phases defined by n-asyn and dopaminergic biomarkers, while Stages 3–6 are defined by clinical features and functional decline ^[200].
Motor Phenotypes: PD is often classified by motor asymmetry, defined as the difference between right and left appendicular motor scores ^[29]^D. While asymmetry is a hallmark of the disease, its trajectory over time (e.g., 5 years post-deep brain stimulation) can impact axial symptoms and quality of life ^[29]^D.
Cognitive Classification: Patients are categorized by cognitive status into PD with normal cognition, PD-Mild Cognitive Impairment (PD-MCI), and Parkinson's Disease Dementia (PDD) ^[197]^[202]. PD-MCI is often identified using Montreal Cognitive Assessment (MoCA)-based Level I screening or more comprehensive Level II neuropsychological batteries ^[197]^[202].
Non-Motor Phenotypes: Classification also includes autonomic subtypes, such as those presenting with supine hypertension (SH) or orthostatic hypotension (OH) ^[4]. Fatigue is another common, though often underdiagnosed, non-motor symptom that significantly affects classification of disease burden ^[204].

Diagnostic and Surveillance Criteria

For epidemiological purposes, case definitions vary. The National Neurological Conditions Surveillance System (NNCSS) utilizes various data sources, including hospital contacts and prescription registries (e.g., redeemed prescriptions for PD medications), to define PD cases for national surveillance ^[7]^[195]. Clinical diagnosis is increasingly supported by the alpha-synuclein Seed Amplification Assay (αSyn-SAA) in cerebrospinal fluid, which demonstrates high concordance with clinical diagnosis even in routine clinical settings ^[27]^D.

NSD Integrated Staging System (NSD-ISS) Overview

Stage	Definition	Primary Criteria
Stage 0	Genetic Risk	Presence of pathogenic variants (e.g., SNCA)
Stage 1	Preclinical	n-asyn (+) and Dopaminergic dysfunction (-)
Stage 2	Prodromal	n-asyn (+) and Dopaminergic dysfunction (+)
Stage 3	Early Clinical	Mild symptoms, no/minimal functional impact
Stage 4-6	Clinical Progression	Increasing functional impairment and severity

Epidemiology and Risk Factors

▸The global prevalence of Parkinson disease is projected to reach 20 million by 2050, with age remaining the most significant risk factor.
▸Environmental factors such as dairy consumption and H. pylori infection increase risk, while residential greenness and potentially GLP-1 receptor agonists show protective associations.
▸PD patients exhibit a 2.35-fold increased risk for fractures and a high prevalence of sarcopenia (43.6%), necessitating early screening for physical frailty.

HY High Yield: While smoking is historically associated with a lower risk of PD, this may be a 'survivor bias' effect; smokers often die from cardiovascular or pulmonary disease before reaching the peak age of PD onset [49].

Parkinson disease (PD) is a progressive neurodegenerative disorder and represents one of the fastest-growing causes of neurological disability worldwide ^[51]^D. The global prevalence is increasing steadily, with projections suggesting that approximately 20 million individuals will be affected by 2050 ^[52]^D. While traditionally viewed through the lens of motor dysfunction, PD is now recognized as a multisystem disorder where non-motor features often precede motor onset by decades, defining a critical prodromal phase ^[51]^D.

Incidence and Prevalence Trends

The of PD exhibits significant temporal and geographic variation. In the United Kingdom, the age-standardized incidence of PD was recorded at 35.61 per 100,000 person-years in 2007, though it showed a slight decrease to 31.27 per 100,000 by 2019 ^[36]. Despite this decrease in incidence, the prevalence has trended upward, peaking at 0.23% in 2016 ^[36]. This rising prevalence is attributed to both an aging global population and improved diagnostic reach ^[31].

Early-onset Parkinson disease (EOPD), defined as onset between ages 21 and 50, imposes a unique burden on productivity and mental health ^[46]^D. While the majority of cases occur in older adults—where age remains the strongest risk factor—the global burden of EOPD has been tracked from 1990 to 2021, showing varied trends based on the Socio-demographic Index (SDI) of different regions ^[46]^D^[54]^D.

Demographic and Genetic Distribution

PD disproportionately affects males, with studies often reporting a male-to-female ratio of approximately 2:1 (e.g., 66.7% male in specific cohorts) ^[39]. Genetic susceptibility plays a role in approximately 20% of cases, primarily linked to pathogenic variants in , , and ^[51]^D. For the remaining 80% of sporadic cases, polygenic risk scores (PRS) are being developed to improve ancestry-informed disease prediction, although current models show modest predictive performance with an AUC ranging from 0.58 to 0.62 ^[48]^D.

Environmental and Lifestyle Risk Factors

The etiology of PD involves a complex interplay between environmental exposures and lifestyle choices.

Smoking and Alcohol: A well-documented inverse relationship exists between smoking and PD risk ^[32]. However, recent competing risk analyses suggest this association may be partially confounded by the higher premature mortality among smokers, which prevents them from reaching the age of PD onset ^[49]^D. The relationship with alcohol remains less clear, requiring dose-response assessments that account for beverage type and sex ^[32].
Dietary Factors: High dairy consumption is associated with an increased risk of PD ^[33]. The mechanism is hypothesized to involve alterations in the gut microbiome and the subsequent spread of along the gut-brain axis ^[33].
Residential Environment: Increased exposure to residential green space and natural environments has been investigated as a potential protective factor, showing an inverse association with PD incidence in large prospective cohorts ^[42].

Infectious and Microbial Associations

Emerging evidence highlights the role of systemic and localized infections in PD pathogenesis.

and Oral Health: Helicobacter pylori infection is significantly more prevalent in PD patients than in healthy controls ^[34]. Similarly, periodontitis and high levels of Porphyromonas gingivalis are strongly associated with PD, with an odds ratio of 3.43 ^[43]. These findings support the "gut-first" or "body-first" hypothesis of PD initiation.
Other Pathogens: Seropositivity for Toxoplasma gondii has been implicated in increased disease severity ^[39]. Furthermore, whole-genome sequencing has identified extensive microbial DNA signatures, predominantly bacterial, in the blood of PD patients, which correlate with disease progression ^[47]^D.

Metabolic and Systemic Comorbidities

Metabolic health significantly influences PD risk and progression. (T2DM) is associated with a higher incidence and faster motor and cognitive decline in PD ^[55]^D^[56]^D. Conversely, the use of incretin-based therapies, such as (e.g., exenatide or liraglutide), may confer neuroprotective effects and reduce PD risk among patients with T2DM ^[35]^[56]^D. Cardiovascular disease (CVD) history also impacts the onset and progression of both motor and non-motor symptoms ^[54]^D.

Associated Risks and Complications

Patients with PD face significantly higher risks for secondary complications compared to matched controls:

Fractures: PD patients have a 2.35 times higher risk of total fractures and a 1.46 times higher risk of vertebral fractures, with a notable predominance in the upper-thoracic (T1-T10) region ^[40].
Autonomic and Sleep Disorders: Orthostatic hypotension (OH) is a frequent autonomic feature that increases the 5-year risk of falls and major vascular events ^[38]. Additionally, PD patients have a significantly higher incidence of sleep-related and somatoform disorders ^[37].
Sarcopenia: The prevalence of sarcopenia in mild-to-moderate PD is estimated at 43.6%, contributing to physical performance decline ^[44]^D.

Table 1: Risk and Protective Factors in Parkinson Disease

Factor	Association	Statistical Measure (95% CI)	Evidence Level
Age	Risk	Strongest individual predictor	2b ^[54]^D
Male Sex	Risk	~2:1 ratio (66.7% male)	3b ^[39]
Periodontitis	Risk	OR 3.43 (1.65–7.13)	3b ^[43]
Vertebral Fracture	Risk (Outcome)	RR 2.35 (Total), RR 1.46 (Vertebral)	3b ^[40]
Dairy Consumption	Risk	Positive association (Gut-brain axis)	2a ^[33]
H. pylori Infection	Risk	Higher prevalence in PD vs controls	2a ^[34]
GLP-1RAs	Protective	Reduced risk in T2DM patients	2a ^[35]
Smoking	Inverse	Inverse association (Mortality-confounded)	2a ^[32], 5 ^[49]^D
Green Space	Protective	Inverse association with incidence	2b ^[42]

Diagnosis and Workup

▸Diagnosis is primarily clinical, requiring bradykinesia plus tremor or rigidity, but clinical accuracy alone is often <93%.
▸Detection of phospho-α-synuclein in skin biopsies at C7/Th12 is a highly specific marker for differentiating PD from tauopathies like PSP.
▸Advanced imaging such as 31P MR spectroscopy and DaTscan provide objective evidence of midbrain energy failure and dopaminergic loss.

Dx Diagnostic Essentials: The clinical identification of bradykinesia combined with a positive response to a Levodopa Challenge (>30% MDS-UPDRS Part III improvement) remains the most critical step in diagnosing idiopathic Parkinson Disease.

HY High Yield: Skin biopsy for S129 phospho-α-synuclein is a definitive way to distinguish synucleinopathies (PD, MSA) from tauopathies (PSP), as the latter will be negative for this marker.

The diagnosis of Parkinson Disease (PD) remains primarily clinical, though the integration of multimodal biomarkers and advanced imaging has significantly improved diagnostic accuracy and the ability to differentiate PD from other synucleinopathies and tauopathies ^[76]^D^[81]^D. While the Unified Parkinson's Disease Rating Scale (UPDRS) is the gold standard for clinical assessment, its accuracy is often <93% due to subjective judgment and the clinical overlap between PD, Multiple System Atrophy (MSA), and (PSP) ^[76]^D^[71]^D.

Diagnostic Criteria

Clinical diagnosis is based on the identification of motor features and the exclusion of secondary causes. The core requirement is bradykinesia (slowness of movement and decrement in amplitude or speed) in combination with at least one of the following: rest tremor (4–6 Hz) or rigidity ^[81]^D.

Supportive Features: A clear and dramatic response to dopaminergic therapy (Levodopa Challenge), the presence of levodopa-induced dyskinesias, and the presence of olfactory loss or sleep disturbances.
Exclusion Criteria: Early severe autonomic dysfunction, prominent supranuclear gaze palsy, or cerebellar signs, which suggest alternative diagnoses like MSA or PSP ^[71]^D^[87]^D.
Levodopa Challenge Protocol:
1. Step 1: Baseline motor assessment using MDS-UPDRS Part III in the "OFF" state (medication withheld for at least 12 hours).
2. Step 2: Administration of a suprathreshold dose of levodopa (typically 150% of the usual morning dose or 200 mg).
3. Step 3: Repeat MDS-UPDRS Part III assessment after 60–90 minutes. A >30% improvement in motor score is considered a positive response supporting a PD diagnosis.

Laboratory Tests and Emerging Biomarkers

While routine blood work is often unremarkable, specific biomarkers are emerging to confirm the underlying pathology of alpha-synuclein aggregation ^[71]^D.

Skin Biopsy (pαSyn): Detection of intraneural S129 phospho-α-synuclein (pαSyn) via immunofluorescence staining in skin biopsies is a highly promising diagnostic tool ^[71]^D. Samples are typically obtained from the C7 and Th12 dermatomes. This test is particularly useful for differentiating synucleinopathies (PD, MSA) from tauopathies (PSP), as pαSyn is absent in the latter ^[71]^D.
Oxidative Stress Markers: Research indicates that glutathione (GSH) depletion in the substantia nigra is a significant contributor to neuronal damage ^[65]. While not yet a routine clinical test, measuring GSH levels and other oxidative biomarkers can provide insight into disease pathophysiology ^[65].
Orthostatic Blood Pressure: Monitoring orthostatic systolic blood pressure (∆SBP) trajectories is essential, as specific longitudinal patterns are associated with heterogeneous disease progression and autonomic failure ^[80]^D.

Neuroimaging

Imaging is utilized both to rule out mimics and to identify specific neurochemical deficits ^[74]^D^[81]^D.

DaTscan ([123I]FP-CIT SPECT): This modality visualizes the striatal dopamine transporter (DAT) density. It is highly effective for validating clinically uncertain and has shown a strong correlation between rest tremor amplitude and DAT binding in the ipsilateral striatum ^[81]^D.
Structural and Functional MRI: Conventional MRI is often normal in early PD but is necessary to exclude secondary parkinsonism. Advanced techniques include:
- Neuromelanin-sensitive MRI: Visualizes the loss of pigmented neurons in the substantia nigra ^[74]^D.
- Quantitative Susceptibility Mapping (QSM): Detects increased iron accumulation in the midbrain, a hallmark of PD oxidative stress ^[74]^D.
- 31P MR Spectroscopy: Evaluates midbrain energy homeostasis by measuring inorganic phosphate (Pi), phosphocreatine (PCr), and adenosine triphosphate (ATP) ^[74]^D.
- Choroid Plexus Volumetrics: Increased choroid plexus volume fraction (CPVF) has been associated with glymphatic dysfunction in PD patients compared to healthy controls ^[82]^D.
Synaptic Density PET: [11C]UCB-J PET imaging targets the synaptic vesicle glycoprotein 2A (SV2A), providing a direct measure of synaptic density, which is reduced in PD ^[85]^D.

Electrodiagnostic and Functional Studies

Electroencephalography (EEG): Decomposed Transfer Entropy (DTE) analysis of resting EEG reveals that the unmedicated (PD-OFF) state is characterized by phase-dominant reweighting of brain networks, particularly originating from the frontal regions ^[75]^D.
Wearable Devices and Gait Analysis: Sensor-based insole systems can detect plantar pressure variability and dual-task gait differences, which are sensitive markers for impaired motor automaticity in early-stage PD ^[73]^D^[61].
Directional OCT: Directional optical coherence tomography (OCT) can detect thinning of the true outer nuclear layer (ONL) in the retina, reflecting neurodegeneration ^[77]^D.

Diagnostic Algorithm

Step	Action	Rationale
1	Clinical Assessment	Identify bradykinesia, tremor, and rigidity using MDS-UPDRS ^[76]^D.
2	Levodopa Challenge	Confirm dopaminergic responsiveness (>30% improvement) ^[64].
3	Structural MRI	Rule out structural mimics (e.g., hydrocephalus, vascular parkinsonism) ^[82]^D.
4	DaTscan	Confirm presynaptic dopaminergic deficit if diagnosis is uncertain ^[81]^D.
5	Skin Biopsy	Differentiate from tauopathies (PSP) via pαSyn detection if clinical overlap exists ^[71]^D.

Diagnostic Test Characteristics in Parkinson Disease

Test	Finding	Timing	Sensitivity/Specificity
MDS-UPDRS	Motor score >30% improvement post-levodopa	Baseline/Follow-up	High sensitivity for PD
DaTscan	Reduced striatal DAT binding	Early to late stage	High sensitivity for dopaminergic loss ^[81]^D
Skin Biopsy	S129 phospho-α-synuclein (pαSyn)	Any stage	High specificity vs. tauopathies ^[71]^D
31P MRS	Altered Pi, PCr, and ATP levels	Early stage	Differentiates PD from mimics ^[74]^D
OCT	Outer nuclear layer (ONL) thinning	Early to mid stage	Reflects neurodegeneration ^[77]^D

Diagnosis and Differential Diagnosis

▸The detection of phospho-α-synuclein in skin biopsies is a critical tool for differentiating synucleinopathies (PD, MSA) from tauopathies (PSP).
▸31P MR spectroscopy provides a metabolic signature of midbrain energy homeostasis that can discriminate early-stage PD from its mimics.
▸Vascular Parkinsonism should be suspected in patients with a high burden of cerebral small vessel disease on MRI, such as extensive white matter hyperintensities.

Dx Diagnostic Essentials: Skin biopsy for S129 phospho-α-synuclein (pαSyn) is the most specific biological test to confirm a synucleinopathy and exclude tauopathies like PSP [71].

HY High Yield: Vascular Parkinsonism (VP) often presents as 'lower-body parkinsonism' with prominent gait impairment and is strongly associated with cerebral small vessel disease (CSVD) on MRI [36, 90].

The diagnosis of Parkinson Disease (PD) remains primarily clinical, centered on the identification of motor features resulting from the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta ^[98]^D^[99]^D. However, the insidious onset and clinical overlap with other neurodegenerative disorders—specifically 'Parkinson-plus' syndromes—necessitate a rigorous diagnostic workup to differentiate idiopathic PD from mimics such as Multiple System Atrophy (MSA), (PSP), and Vascular (VP) ^[36]^[71]^D. Recent advancements in molecular biomarkers, such as skin biopsies for phospho-α-synuclein and advanced phosphorus MR spectroscopy, have significantly enhanced diagnostic precision ^[71]^D^[74]^D.

Diagnostic Criteria

Formal diagnosis requires the presence of bradykinesia (slowness of movement and decrement in amplitude or speed) in combination with at least one of the following: resting tremor (4–6 Hz) or rigidity ^[99]^D.

Required Features: Bradykinesia is the essential motor sign. It must be documented through repetitive movements (e.g., finger tapping, hand movements) ^[99]^D.
Supportive Features: A clear and dramatic response to dopaminergic therapy, the presence of levodopa-induced dyskinesia, or the presence of olfactory loss (hyposmia) ^[98]^D.
Exclusion Criteria (Red Flags): Early-onset postural instability (falls within the first 3 years), rapid progression of gait impairment, symmetric motor signs at onset, or prominent autonomic dysfunction (suggestive of MSA) ^[71]^D^[90].

Laboratory Tests

While routine blood work is often normal, specialized molecular and genetic testing provides critical diagnostic clarity.

Skin Biopsy (pαSyn): Detection of S129 phospho-α-synuclein (pαSyn) via immunofluorescence staining in skin biopsies (typically taken from C7 and Th12 sites) is a highly specific marker for synucleinopathies ^[71]^D. This test distinguishes PD and MSA from tauopathies like PSP, which do not exhibit pαSyn accumulation ^[71]^D.
Genetic Testing: Although 85% of cases are idiopathic, screening for rare mutations in the DNAJC family (e.g., DNAJC6, DNAJC13) or common variants like SLC39A8 (rs13107325) can identify familial forms or genetic predispositions ^[107]^D^[108]^D.
Speech Signal Analysis: Acoustic analysis of speech signals can differentiate PD from Alzheimer's Disease (AD) and depression. PD is characterized by specific alterations in Jitter (frequency variability) and Shimmer (amplitude variability) ^[102].

Imaging

Imaging is utilized to exclude secondary causes of parkinsonism and to identify metabolic signatures of PD.

31P MR Spectroscopy: This modality evaluates midbrain energy homeostasis. Patients with early-stage PD exhibit distinct levels of inorganic phosphate (Pi), phosphocreatine (PCr), and adenosine triphosphate (ATP) compared to healthy controls and mimics ^[74]^D. Integrating 31P spectroscopy with conventional 1H MRI improves the discrimination of PD from other parkinsonian syndromes ^[74]^D.
Structural MRI and CSVD: Conventional MRI is used to assess Cerebral Small Vessel Disease (CSVD) burden, including white matter hyperintensities (WMH), lacunes, and cerebral microbleeds ^[90]. A high CSVD burden is more characteristic of Vascular Parkinsonism (VP), though it also correlates with worse motor and gait scores in idiopathic PD ^[90].
Neuromelanin-sensitive MRI: This technique can visualize the loss of pigmented neurons in the substantia nigra, a hallmark of PD pathology ^[74]^D.

Electrodiagnostic Studies

EEG Brain Networks: Decomposed Transfer Entropy (DTE) analysis of resting-state EEG (specifically in the theta band) reveals altered directed information flow in unmedicated PD patients ^[75]^D. This phase-dominant reweighting of brain networks can help characterize the neurophysiological state of the disease ^[75]^D.
Plantar Pressure Variability: Using sensor-based insole systems, clinicians can detect impaired motor automaticity. Early-stage PD is characterized by significant plantar pressure alterations during dual-task walking (e.g., walking while performing a cognitive task), which is more sensitive than conventional spatiotemporal gait metrics ^[73]^D.

Diagnostic Algorithm

Step 1: Clinical Screening → Identify core motor symptoms (bradykinesia, tremor, rigidity) and assess for non-motor symptoms like hyposmia or sleep disorders ^[98]^D^[99]^D. Step 2: Identify Red Flags → Evaluate for early falls, rapid progression, or poor levodopa response to rule out Parkinson-plus syndromes ^[71]^D. Step 3: Advanced Imaging/Biopsy → Order 31P MR spectroscopy to assess midbrain energy levels ^[74]^D or a skin biopsy for pαSyn to confirm a synucleinopathy ^[71]^D. Step 4: Phenotype Characterization → Determine if the presentation is 'body-first' (originating in the GI tract via the vagus nerve) or 'brain-first' based on the sequence of non-motor vs. motor symptom onset ^[98]^D.

Differential Diagnosis of Parkinsonian Syndromes

Feature	Parkinson Disease (PD)	Multiple System Atrophy (MSA)	Progressive Supranuclear Palsy (PSP)	Vascular Parkinsonism (VP)
Primary Pathology	α-Synuclein ^[93]^D	α-Synuclein ^[71]^D	Tau protein ^[71]^D	Ischemic/Vascular ^[90]
Skin Biopsy (pαSyn)	Positive ^[71]^D	Positive ^[71]^D	Negative ^[71]^D	Negative
Levodopa Response	Excellent/Sustained	Poor or Transient	Poor	Variable/Poor
Early Falls	Rare	Occasional	Characteristic/Early	Common
Imaging Findings	Midbrain ATP/Pi changes ^[74]^D	Autonomic atrophy	'Hummingbird' sign	High CSVD/WMH burden ^[90]
Speech Changes	Hypokinetic dysarthria ^[101]	Stridor/Dysarthria	Spastic dysarthria	Lower-half parkinsonism

Management of Parkinson Disease

▸Levodopa timing is critical; even brief delays in administration in acute settings like the ED can lead to severe morbidity [28].
▸Symmetric Parkinson's disease is a predictor of poorer outcomes for both dopaminergic medication and subthalamic deep brain stimulation [122].
▸Non-pharmacological interventions like cycling (40-60 min 3x/week) and high-intensity respiratory training (60% MIP/MEP) are evidence-based treatments for urinary and swallowing dysfunction, respectively [112, 67].

Rx Drug of Choice: Carbidopa-Levodopa (25/100 mg) remains the primary treatment. Strict adherence to dosing schedules is mandatory to prevent acute decompensation [28].

! Warning: STN-DBS may be less effective in patients with symmetric motor signs; these patients often experience faster disease progression and poorer ADL outcomes post-surgery [122].

The of Parkinson Disease (PD) requires a multi-modal approach that integrates pharmacological optimization, surgical intervention, and targeted rehabilitation to address both motor and non-motor symptoms (NMS) ^[124]^D. Because PD is a progressive neurodegenerative disorder, treatment must be dynamic, transitioning from symptomatic relief in early stages to complex management of motor fluctuations and cognitive changes in advanced disease ^[95]^D^[124]^D.

Step 1: Initial Assessment and Severity Classification

Clinicians must first classify the disease phenotype and severity to determine the appropriate intervention path. A critical diagnostic distinction is the degree of motor asymmetry; approximately 20% of patients present with symmetric motor signs, which are associated with faster progression and a poorer response to dopaminergic therapy and (DBS) ^[122]^D.

Mild/Early PD: Focus on initiating monotherapy (MAO-B inhibitors or low-dose Levodopa) and establishing exercise routines ^[112].
Moderate/Advanced PD: Management of "wearing-off" phenomena and dyskinesias ^[114].
Non-Motor Dominant: Prioritizing neuropsychiatric, autonomic, and sleep disturbances ^[6]^[112]^[115].

Step 2: Optimization of Dopaminergic Therapy

remains the gold standard for motor symptom control. In the acute or Emergency Department (ED) setting, maintaining the outpatient regimen of Carbidopa-Levodopa (e.g., 25/100 mg TID) is critical; delays or omissions in administration are associated with significant morbidity and increased mortality ^[28]^D.

For patients experiencing motor fluctuations, adjunctive therapies are utilized. While traditional pharmacological adjustments (COMT inhibitors, Amantadine) are standard, emerging evidence supports the use of repetitive transcranial magnetic stimulation (rTMS) and theta-burst stimulation (TBS) to enhance motor outcomes ^[114]. Specifically, multi-session continuous TBS (cTBS) has demonstrated significant superiority over single-session protocols in improving motor function (Level 2a) ^[114].

Step 3: Targeted Management of Non-Motor Symptoms (NMS)

NMS often impact quality of life more severely than motor deficits. Management should follow symptom-specific protocols:

Urinary Dysfunction: Implement a cycling exercise protocol consisting of three 40-60 minute sessions per week. This has been shown to significantly reduce urinary frequency in early PD ^[112].
Depression: For patients with mild-to-moderate PD and depressive symptoms, High-Definition Transcranial Direct Current Stimulation (HD-tDCS) is recommended. The protocol involves two 20-minute sessions of anodal stimulation targeting the left dorsolateral prefrontal cortex, separated by a 30-minute interval ^[6].
Respiratory and Swallowing Dysfunction: To prevent , clinicians should prescribe High-Intensity Expiratory Muscle Strength Training (EMST) at 60% of maximal expiratory pressure (MEP) ^[67]. Adherence is significantly improved when utilizing mHealth-assisted platforms like the SpiroGym app ^[63].
Symptoms: In drug-naïve patients, Donor (dFMT) may be considered. The protocol involves 200 mL on days 1-3 followed by 50 mL on days 4-7 per 4-week cycle to improve both motor and GI symptoms via the gut-brain axis ^[117].

Step 4: Advanced Surgical Interventions (DBS)

Bilateral DBS of the subthalamic nucleus (STN) is indicated for patients with advanced PD and medication-refractory motor fluctuations ^[92].

Mechanism and Benefits: STN-DBS not only improves motor scores but also significantly enhances sleep architecture by reducing REM latency ^[115].
Programming: Traditional trial-and-error programming is being replaced by tractography-guided contact selection (targeting the dentato-rubro-thalamic tract) and computational models to reduce the 12-month optimization window ^[92]^[116].
Caveats: Clinicians must monitor for the "microlesion effect" (MLE) post-surgery, which can cause transient cognitive dysfunction, particularly in verbal fluency ^[84]^D. Patients with symmetric PD symptoms generally experience less improvement in activities of daily living (ADL) following STN-DBS compared to those with asymmetric disease ^[122]^D.

Step 5: Integrative Rehabilitation and Emerging Therapies

Standard pharmacological care should be supplemented with proprioceptive and sensory-based interventions:

Gait and Balance: Transcutaneous auricular vagus nerve stimulation (taVNS) is an effective noninvasive therapy for improving gait parameters ^[111]. For postural instability, Focal Muscle Vibration (fMV) and Immersive Virtual Reality (IVR) training are utilized to reduce visual dependency and fall risk ^[118]^[83]^[69].
Speech Therapy: Singing-based interventions are recommended for treating hypokinetic dysarthria, improving vocal intensity and articulation ^[101].
Fatigue: Color therapy, involving 15-minute exposures to purple, yellow, and orange light (totaling 45 minutes), has shown efficacy in reducing fatigue and depression ^[68].

Comparison of Targeted Interventions for PD Symptoms

Intervention	Target Symptom	Dose/Protocol	Evidence Level
Carbidopa-Levodopa	Motor Symptoms	25/100 mg (Standard starting)	1a ^[28]^D
STN-DBS	Motor/Sleep	Bilateral stimulation	2a ^[115]
Donor FMT	Motor/GI	200mL (D1-3), 50mL (D4-7)	1b ^[117]
HD-tDCS	Depression	20 min anodal, 2 sessions	1b ^[6]
Cycling	Urinary Frequency	40-60 min, 3x/week	1b ^[112]
taVNS	Gait/Motor	Noninvasive stimulation	1a ^[111]

Supportive Care and Complication Management

▸Parkinson's disease is projected to affect 25 million people by 2050, necessitating scalable supportive care.
▸Structured walking interventions must exceed 3 weeks or 6 sessions to significantly impact gait parameters.
▸Virtual reality (VR) and gamified environments improve dual-task performance and gait speed in mild-to-moderate PD.
▸Transcutaneous auricular vagus nerve stimulation (taVNS) is an emerging non-invasive therapy for both motor and autonomic symptoms.
▸Cycling exercise specifically targets urinary frequency in early-stage Parkinson's disease.
▸mHealth applications improve long-term adherence to respiratory exercises (EMST), reducing aspiration risk.
▸Suprascapular nerve block with pulsed radiofrequency is effective for PD-related chronic shoulder pain.

CP Clinical Pearl: When prescribing exercise for early PD, cycling for 40-60 minutes three times weekly may specifically help manage worsening urinary frequency [112].

! Warning: Aspiration pneumonia remains a leading cause of mortality; clinicians should prioritize expiratory muscle strength training (EMST) and consider mHealth tools to ensure patient adherence [63].

HY High Yield: Gait impairments in PD often worsen under cognitive load (dual-tasking). Interventions combining treadmill training with virtual reality (VR) are specifically designed to address this capacity-performance gap [205, 208].

Overview of Multidisciplinary Rehabilitation

Supportive care in Parkinson’s disease (PD) has evolved from a limited evidence base to a robust field with over 240 randomized controlled trials (RCTs) as of 2026 ^[207]. While pharmacologic management effectively addresses motor symptoms, patients frequently identify walking, mobility, and balance as their primary challenges ^[207]. Modern supportive care emphasizes bridging the "capacity-performance gap" by translating clinical gains into real-world functional improvements ^[207].

Physical Therapy and Exercise Modalities

Exercise is a critical non-pharmacological intervention, with network meta-analyses identifying specific modalities and doses that optimize quality of life (QOL) ^[140].

Walking Interventions: Structured voluntary walking programs (typically >3 weeks or >6 sessions) significantly improve gait velocity, distance, and step length ^[206]. These interventions also enhance functional mobility and health-related QOL compared to non-active controls ^[206].
Reactive and Strength Training: Home-based time-constrained reactive training (e.g., visually guided reaching and stepping) has been shown to enhance movement speed in both upper and lower limbs by upregulating movement vigor ^[129]. Rebound therapy, involving task-oriented exercises on a trampoline, has demonstrated efficacy in improving balance and knee strength compared to stable-surface exercises ^[130].
Specialized Gait Training: The use of sequential square mats (e.g., Fisior®) for progressive balance and resistance training over 12 weeks significantly improves gait speed and physical performance ^[213].
Cycling: For early-stage PD, cycling exercise (40-60 minutes, 3 times per week) has been shown to selectively benefit autonomic symptoms, specifically reducing the progression of urinary frequency ^[112].

Digital Health and Virtual Reality (VR)

Technological integration is increasingly used to address gait impairments that persist despite medication ^[208]^C.

Virtual Reality (VR) and Treadmill Training: VR protocols (ranging from 5 to 12 weeks) improve balance, gait speed, and dual-task performance ^[205]. Combining treadmill training with gamified virtual reality environments (GVRE) addresses both motor and cognitive contributors to gait impairment ^[208]^C. Non-immersive VR (NIVR) using semi-spherical balance devices has also proven effective in reducing MDS-UPDRS Part III scores over 12 weeks ^[210].
Exergaming: Universally designed exergame programs are feasible even for patients in moderate to advanced stages (Hoehn & Yahr III-V), providing a supervised rehabilitation option in care facilities ^[128].
Telerehabilitation: Individualized real-time physiotherapy delivered via videoconference is a feasible alternative for early-stage PD, potentially lowering costs while maintaining clinician-led exercise prescription ^[212]^C.

Neuromodulation in Rehabilitation

Non-invasive stimulation techniques are being investigated as adjuncts to standard physical therapy (PT).

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS): Meta-analyses and RCTs indicate that taVNS improves motor function (MDS-UPDRS III), gait parameters, and non-motor symptoms like sleep and QOL ^[111]^[131]. Neuroimaging suggests taVNS may decrease glutamate levels in the striatum and thalamus ^[131].
Transcranial Direct Current Stimulation (tDCS): When combined with GVRE and treadmill training, tDCS may enhance executive function under dual-task conditions ^[208]^C. However, its ability to enhance the efficacy of specific physiotherapy for Freezing of Gait (FOG) has shown mixed results in small-scale trials ^[127].
Intermittent Theta-Burst Stimulation (iTBS): Applying bilateral M1-iTBS twice daily for 2 weeks as a "cortical priming" agent has been explored to enhance the responsiveness of the brain to subsequent physical therapy ^[209].

Management of Non-Motor Complications

Pain Management: Chronic pain is a debilitating non-motor symptom. Combining Transcutaneous Electrical Nerve Stimulation (TENS) with exercise programs may reduce pain intensity and fatigue ^[214]. For chronic shoulder pain (subacromial pain syndrome) in PD, ultrasound-guided suprascapular nerve block combined with pulsed radiofrequency (PRF) has shown clinical efficacy ^[215].
Respiratory and Swallowing Function: Expiratory muscle strength training (EMST) is used to prevent aspiration pneumonia, a leading cause of death in PD ^[63]. Adherence to these protocols can be significantly improved through mHealth interventions and mobile applications ^[63].
Palliative Care: Community-based palliative care interventions have demonstrated benefits in improving QOL, particularly in underserved populations (low-income, rural, or ethnic minorities) ^[211].

Comparison of Emerging Rehabilitative Technologies

Intervention	Target Symptom	Evidence Level	Key Finding
VR Treadmill	Gait & Dual-task	1a	Improves balance and gait speed over 5-12 weeks ^[205].
taVNS	Motor & Autonomic	1a/1b	Reduces MDS-UPDRS III; improves sleep and QOL ^[111]^[131].
Exergaming	General Mobility	4	Feasible for advanced stages (H&Y III-V) ^[128].
mHealth EMST	Respiratory/Swallowing	2b	Enhances adherence to prevent aspiration pneumonia ^[63].
TENS + Exercise	Chronic Pain	1b	Reduces pain intensity and fatigue in PD ^[214].

Special Populations in Parkinson Disease

▸Early-Onset Parkinson Disease (onset 21–50 years) requires a management strategy that prioritizes the delay of motor fluctuations and dyskinesias, which occur more frequently than in late-onset cases.
▸Elderly patients with PD have a nearly threefold increased risk of upper-thoracic vertebral fractures, necessitating early bone density screening and aggressive osteoporosis management.
▸Continuous subcutaneous apomorphine infusion is an effective palliative strategy for maintaining comfort in advanced PD patients who can no longer tolerate oral medications.

HY High Yield: In the Emergency Department, timely administration of carbidopa-levodopa is critical; delays or omissions are common and significantly increase morbidity in elderly PD patients [28].

! Warning: Dysphagia is a leading cause of morbidity in advanced PD; clinicians must proactively screen for swallowing dysfunction to prevent aspiration pneumonia [153].

Parkinson disease (PD) exhibits significant clinical heterogeneity, necessitating tailored strategies for specific patient subgroups. While the classic presentation involves older adults, the rising global burden of (EOPD) and the unique complications faced by the very elderly, pregnant patients, and those with specific comorbidities require distinct clinical approaches ^[46]^D^[154]^D.

Early-Onset Parkinson Disease (EOPD)

EOPD is defined by a symptom onset between the ages of 21 and 50 years ^[154]^D^[46]^D. This population accounts for a significant portion of the global PD burden, with incidence and prevalence rates showing varied temporal trends across different socio-demographic regions ^[46]^D.

Clinical Presentation and Diagnosis Compared to late-onset Parkinson disease (LOPD), EOPD patients are more likely to present with focal and have a higher prevalence of monogenic risk factors ^[154]^D. While motor progression is typically slower in EOPD, these patients experience higher rates of non-motor symptoms such as and ^[154]^D. Diagnostic delays are more common in this group, often because clinicians do not initially suspect neurodegeneration in younger adults ^[154]^D. Recent advancements in diagnostic tools, such as the detection of intraneural S129 phospho-α-synuclein (pαSyn) in skin biopsies, show promise in differentiating synucleinopathies like PD from tauopathies, which is critical for early-stage EOPD management ^[71]^D^[162]^D.

Management Modifications Therapeutic strategies in EOPD must prioritize the long-term prevention of motor complications. Younger patients have a significantly higher risk of developing early -induced dyskinesias and motor fluctuations ^[154]^D.

Feature	Early-Onset PD (21–50 years)	Late-Onset PD (>50 years)
Genetic Basis	Higher prevalence of monogenic variants ^[154]^D	Mostly sporadic; GBA1 variants common ^[151]
Motor Progression	Slower rate of decline ^[154]^D	Faster progression; higher H&Y stages ^[151]
Cognitive Decline	Lower initial risk ^[154]^D	Higher risk; associated with PDD ^[165]^D
Dyskinesia Risk	High; occurs earlier in treatment ^[154]^D	Lower; occurs later in treatment ^[154]^D

Pregnancy and Reproductive Health

Pregnancy in PD is a unique challenge primarily seen in the EOPD population. Management requires a delicate balance between maternal motor stability and fetal safety ^[154]^D.

Clinical Reasoning for Management

Teratogenicity Assessment: Most antiparkinsonian medications lack large-scale human safety data. Levodopa is generally considered the mainstay, but doses must be monitored closely as physiological changes in pregnancy (e.g., increased plasma volume) may alter drug pharmacokinetics ^[154]^D.
Delivery Planning: While PD does not typically contraindicate vaginal delivery, severe motor fluctuations or dystonia may complicate the second stage of labor. Multidisciplinary coordination between neurology and obstetrics is essential ^[154]^D.
: The safety of dopamine agonists during breastfeeding is limited, as these agents can suppress prolactin secretion and inhibit lactation ^[154]^D.

The Elderly and Frail Population

In patients aged 65 and older, PD management is complicated by multimorbidity, increased sensitivity to medication side effects, and a high risk of falls ^[152]^[163]^D. The Triglyceride-Glucose Frailty Index (TyGFI) has emerged as a potential biomarker to identify older adults at higher risk for PD-related functional decline ^[163]^D.

Bone Health and Fracture Risk Elderly PD patients face a profound risk of fractures due to the combination of postural instability and reduced bone mineral density (BMD) ^[152]. Approximately 3% of individuals newly diagnosed with PD sustain a fragility fracture within the first year of diagnosis ^[152]. Notably, PD patients exhibit a nearly threefold higher risk of upper-thoracic (T1-T10) vertebral fractures compared to age-matched controls ^[40].

Protocol for Bone Health Management in Elderly PD

Step 1: Perform baseline Dual-energy X-ray Absorptiometry (DXA) scanning at the time of PD diagnosis ^[152].
Step 2: Initiate Vitamin D and Calcium supplementation for all patients with restricted mobility or low BMD ^[152].
Step 3: Evaluate the need for bisphosphonates or other osteoporosis therapies, particularly in patients with a history of falls or those in Hoehn & Yahr (H&Y) stages III-V ^[151]^[152].

Immunocompromised and Infectious Considerations

Emerging evidence suggests the immune system plays a pivotal role in PD pathogenesis. The peripheral immune landscape, including clonal CD8+ T cells in the leptomeninges, appears altered in neurodegenerative states ^[167]^D.

Infectious Associations Chronic infections may influence PD severity. Research indicates that Toxoplasma gondii seropositivity is associated with PD, although its direct impact on the rate of motor decline is still under investigation ^[39].

Immunomodulatory Therapy Given the role of neuroinflammation, the use of immunosuppressants like azathioprine has been investigated. In the AZA-PD Phase 2 trial, researchers evaluated whether broad peripheral immunosuppression could slow disease progression in early-stage patients, reflecting a shift toward targeting the immune system as a disease-modifying strategy ^[150].

Advanced Disease and Palliative Care

In the terminal phases of PD or other degenerative parkinsonian syndromes (DPS), such as , the loss of the oral route due to severe necessitates alternative delivery methods ^[153]^D^[166]^D.

Protocol for Terminal Phase Symptom Control

Step 1: Assess swallowing safety using fiberoptic endoscopic evaluation of swallowing (FEES) or videofluoroscopy ^[153]^D.
Step 2: If the oral route is compromised by a life-threatening event, transition to Continuous Subcutaneous Apomorphine Infusion (CSAI) to maintain motor comfort and reduce rigidity-related pain ^[166]^D.
Step 3: Implement community-based multisectoral interventions to support both the patient and family caregivers, focusing on quality of life (QoL) and social support ^[155].

Fracture Risk and Mortality Factors in Elderly PD

Factor	Clinical Impact	Evidence Level
Fragility Fracture	3% risk within 1 year of diagnosis ^[152]	2b
Upper-Thoracic Fracture	RR 2.97 compared to controls ^[40]	3b
Type 2 Diabetes	Associated with decreased survival ^[151]	2b
GBA1 Variants	Higher mortality and faster progression ^[151]	2b
High LEDD	Correlates with increased mortality risk ^[151]	2b

Guidelines and Resources

▸A consensus roadmap for balance dysfunction integrates video-oculography and posturography for better clinical translation [216].
▸Hospitalized PD patients require strict adherence to medication timing and dysphagia screening to prevent complications [181, 187].
▸Physical therapy is highly recommended as a complement to STN-DBS to manage axial symptoms and gait impairments [179].
▸GBA1 variants are the most common genetic risk factor, requiring standardized counseling and risk communication [170].
▸Continuous subcutaneous apomorphine infusion (CSAI) management should be tailored to one of five specific patient profiles [217].
▸Long-distance air travel requires personalized planning to mitigate temporary worsening of parkinsonian symptoms [191].

Dx Diagnostic Essentials: Dysphagia in hospitalized PD patients is frequently 'silent' (lacking overt clinical signs) and must be proactively screened to avoid medication delays and aspiration [187].

CP Clinical Pearl: The 'Parkinson’s day-clinic' model is an emerging care standard for advanced PD patients who require multidisciplinary optimization without full hospitalization [218].

! Warning: High-altitude air travel may cause temporary symptom worsening due to dehydration and hypoxic effects on oxyhemoglobin saturation [191].

Clinical Practice Guidelines and Consensus Roadmaps

Recent international consensus efforts have focused on standardizing the management of complex Parkinson's disease (PD) symptoms. A 2026 consensus roadmap emphasizes a multimodal approach to balance dysfunction, integrating video-oculography, vestibular-evoked myogenic potentials (VEMPs), posturography, and perceptual paradigms to improve clinical translation ^[216]. For cognitive disorders, 2026 best practice guidelines provide 51 evidence-based recommendations for standardized diagnosis and evaluation across clinical contexts ^[168]. Additionally, the German Society of Neurology updated its 2023 guidelines to provide specific evidence-based management for autonomic failure, pain, and sleep disturbances ^[169].

Hospitalization and Specialized Care Models

Inpatient care for patients with PD requires specialized protocols to mitigate risks of medication timing errors, contraindicated medications, restricted mobility, and dysphagia ^[181]. Expert recommendations for managing dysphagia during hospital admission emphasize that this symptom is often underrecognized and requires collaborative intervention from neurology, otolaryngology, and speech-language pathology to prevent motor deterioration ^[187]^D. To address the limitations of ambulatory care for advanced PD, the "Parkinson’s day-clinic" has been introduced as a medical care model for patients who do not require full inpatient support but need intensive, personnel-heavy therapeutic options ^[218].

Advanced Therapies and Device-Aided Management

Guidelines for device-aided therapies continue to evolve globally. In France, a Delphi consensus established five distinct patient profiles to guide the initiation and optimization of continuous subcutaneous apomorphine infusion (CSAI) ^[217]. Conversely, experts in Poland have highlighted significant gaps in equitable access, noting that rescue apomorphine pens and certain intestinal gel infusions remain unreimbursed in some regions ^[220]. For patients treated with subthalamic deep brain stimulation (STN-DBS), a 2025 Delphi study strongly recommends physical therapy to address dopamine-resistant symptoms such as postural instability and freezing of gait ^[179]. In Portugal, expert consensus has been reached on the optimal clinical application of safinamide for managing motor fluctuations ^[219].

Non-Motor and Palliative Care

Management of non-motor symptoms remains a priority for improving quality of life. The Brazilian Academy of Neurology has developed specific recommendations for neuropsychiatric symptoms, including depression, anxiety, and psychosis ^[175]. Bone health is also a critical concern; a systematic review of clinical guidelines for osteoporosis in PD identifies a high fracture risk due to the combination of low bone mineral density and frequent falls ^[174]. Regarding end-of-life care, a thematic synthesis suggests that palliative care (PC) should be introduced early, though significant organizational barriers to timely access remain ^[178].

Travel and Genetic Counseling

Specific guidance now exists for patients undertaking long-distance air travel, which can temporarily worsen motor and non-motor states due to dehydration, hypoxia, and jet lag; personalized pre-travel planning is essential ^[191]^D. In the realm of genetics, consensus guidance for GBA1 variants—the most common genetic risk factor for PD—now provides a framework for communicating PD risk and navigating the practicalities of genotyping ^[170].

Diagnostic Biomarkers and Emerging Technology

Diagnostic accuracy is being refined through network meta-analyses of cerebrospinal fluid (CSF) biomarkers, which help differentiate PD from atypical parkinsonian syndromes ^[177]. Neuroimaging research has identified altered regional spontaneous brain activity through meta-analysis of rs-fMRI indicators like ALFF and ReHo ^[176]. Furthermore, the burden of cerebral small vessel disease (CSVD), including white matter hyperintensities and microbleeds, has been shown to correlate with worse motor and gait scores in PD cohorts ^[90]. To improve reliability in clinical settings, computer vision-based automated systems are being developed to provide objective motor severity estimation and reduce inter-rater variability ^[221].

Progression Thresholds

Defining meaningful clinical change is vital for trial design and long-term management. Recent anchor-based analyses and clinical consensus have established a meaningful motor progression threshold on the MDS-UPDRS Part III in the OFF medication state to better understand early disease progression ^[222].

Key Management Domains in Recent Guidelines

Domain	Primary Focus	Reference
Cognition	Standardized diagnosis and evaluation of PD cognitive disorders	^[168]
Hospital Care	Medication timing, mobility, and dysphagia management	^[181], ^[187]^D
Advanced Therapy	Optimization of continuous apomorphine infusion (CSAI)	^[217]
Non-Motor	Autonomic failure, pain, and sleep disturbances	^[169], ^[175]
Bone Health	Osteoporosis screening and fracture prevention	^[174]
Travel	Mitigation of hypoxia and jet lag effects during long-haul flights	^[191]^D

References

[1]
Gregson CL, Armstrong DJ, Avgerinou C et al.. “The 2024 UK clinical guideline for the prevention and treatment of osteoporosis.” Archives of osteoporosis (2025). PMID: 40921943 ↗
L1cGUIDELINECited in: Definition, Synonyms, and Classification
[2]
Xavier D, Felizardo V, Ferreira B et al.. “Voice analysis in Parkinson's disease - a systematic literature review.” Artificial intelligence in medicine (2025). PMID: 40132400 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification
[3]
Bradley M, O'Loughlin S, Donlon E et al.. “Determining Falls Risk in People with Parkinson's Disease Using Wearable Sensors: A Systematic Review.” Sensors (Basel, Switzerland) (2025). PMID: 40648326 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification
[4]
Moss Lopes PR, Westphal Filho FL, Mendes Filho FSM et al.. “Prevalence of Supine Hypertension in Alpha-Synucleinopathies: A Systematic Review and Meta-Analysis.” Movement disorders clinical practice (2025). PMID: 40406920 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification
[5]
Pecoraro PM, Marsili L, Espay AJ et al.. “Computer Vision Technologies in Movement Disorders: A Systematic Review.” Movement disorders clinical practice (2025). PMID: 40326633 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification
[6]
Sharma P, Singh SM, Mehta S et al.. “High-definition transcranial direct current stimulation for depressive and other non-motor symptoms in Parkinson's disease: a randomised, sham-controlled, cross-over study.” East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan (2026). PMID: 41916935 ↗
L1bRCTCited in: Definition, Synonyms, and Classification, Diagnosis and Workup, Differential Diagnosis, Management
[7]
Cole-Hunter T, Antic S, Lim YH et al.. “Long-Term Exposure to Air Pollution and Incidence of Parkinson's Disease: A Danish Nationwide Administrative Cohort Study.” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 41772748 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification
[8]
Davydow DS, Okun MS, Pontone GM. “Potential Risk Factors for Psychosis in Parkinson's Disease: A Review of Cohort and Case-Control Studies.” Journal of geriatric psychiatry and neurology (2025). PMID: 39925085 ↗
L3bCASE_CONTROLCited in: Definition, Synonyms, and Classification
[9]
Gilat M, Nonnekes J, Factor SA et al.. “An updated definition of freezing of gait.” Nature reviews. Neurology (2026). PMID: 41513745 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Guidelines and Resources
[10]
Rigon L, Poplawska-Domaszewicz K, Metta V et al.. “The challenges with the identification of Parkinson's disease subtypes.” Expert review of neurotherapeutics (2026). PMID: 41474600 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
[11]
Bougea A. “Staging and markers in Parkinson's disease and Lewy body disorders: narrative review.” Therapeutic advances in chronic disease (2025). PMID: 41146744 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
[12]
Ma H, Zhu Y, Zhao X et al.. “Pyroptosis: inflammatory cell death mechanism and its pathological roles in neurological diseases and injuries.” Apoptosis : an international journal on programmed cell death (2025). PMID: 40813542 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
[13]
Factor SA, Weinshenker D, McKay JL. “A possible pathway to freezing of gait in Parkinson's disease.” Journal of Parkinson's disease (2025). PMID: 39973500 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
[14]
Höglinger GU, Lang AE. “SynNeurGe: The road ahead for a biological definition of Parkinson's disease.” Journal of Parkinson's disease (2025). PMID: 39973492 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
[15]
Bendetowicz D, Planche V, Bezard E et al.. “Biological definitions of synucleinopathies should be anchored in clinical trajectories and encompass the complex biology of the disease.” Journal of Parkinson's disease (2025). PMID: 39973487 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
[16]
Tinazzi M, Geroin C, Siciliano M et al.. “Pain and fatigue in Parkinson's disease: advances in diagnosis and management.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 39937423 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
[17]
Soto C, Mollenhauer B, Hansson O et al.. “Toward a biological definition of neuronal and glial synucleinopathies.” Nature medicine (2025). PMID: 39885358 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
[18]
Lesley R, Simpson J, Dale M et al.. “Predictors of Informal Caregiver Burden in Parkinson's Disease: A Systematic Review.” Western journal of nursing research (2025). PMID: 40138495 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification
[19]
Cataldo E, de Oliveira Aguiar AG, Silva LAS. “A Methodological Review of Voice Acoustic Parameters, with Emphasis on Vocal Tremor: Definitions, Computation, and Software Tools.” Journal of voice : official journal of the Voice Foundation (2026). PMID: 41951462 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
[20]
Fan SP, Okuzumi A, Chen PS et al.. “Parkinson's disease in transition: Genetics, biomarkers, and emerging therapeutics.” Journal of the Formosan Medical Association = Taiwan yi zhi (2025). PMID: 41353001 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
[21]
Calzetti S, Calzetti G. “The nosology of tardive parkinsonism.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 41130187 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
[22]
Subramanian I, Ricciardi L, Schrag A et al.. “A Holistic Wellness Prescription for Parkinson's Disease: Evidence-Based Perspectives and Unmet Needs.” Movement disorders clinical practice (2026). PMID: 41084417 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
[23]
Brenlla C, Lazaro-Hernandez C, Fernandez M et al.. “Biomarkers of neurodegenerative parkinsonisms: From current clinical to future biological definitions - literature review and our experience.” Neurologia i neurochirurgia polska (2025). PMID: 40207871 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
[24]
Markiewicz M, Madetko-Alster N, Alster P. “Quality of life in patients with progressive supranuclear palsy: a review of literature and implications for practice.” Frontiers in neurology (2024). PMID: 39634776 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
[25]
Stinson SE, Shadrin AA, Rahman Z et al.. “Distinct metabolic signatures of Alzheimer's and Parkinson's disease revealed through genetic overlap.” EBioMedicine (2026). PMID: 41966729 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[26]
Ekert JO, Patel V, Zhou X et al.. “Enhancing 7T MRI for deep brain stimulation with deep-learning based image reconstruction and dynamic parallel transmission.” NeuroImage. Clinical (2026). PMID: 41962172 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[27]
Dinter E, Margraff JL, Schniewind I et al.. “CSF alpha-Synuclein Seed Amplification Assay results in routine clinically collected samples.” Journal of Parkinson's disease (2026). PMID: 41944207 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[28]
Elder NM, Lash EM, Tomkins-Tinch C. “An Underrecognized Problem: Missed and Delayed Carbidopa-Levodopa Administration in Emergency Department Patients With Parkinson's Disease.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2026). PMID: 41910596 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Management, Special Populations
[29]
Barbosa RP, Bastos P, Béreau M et al.. “Is being asymmetric a bad thing? Insights from a longitudinal observational study on STN-DBS Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41887013 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[30]
Park D, Lee WR, Bang M et al.. “Impact of Postoperative Chronic Back Pain Syndrome on the Incidence of Psychiatric and Brain Disorders, and All-Cause Mortality.” Journal of pain research (2026). PMID: 41710284 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[31]
Liu R, Zhang S, Xiao Y et al.. “The Effects of Digital Health Interventions on Motor Symptoms, Nonmotor Symptoms, and Quality of Life in Patients With Parkinson Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Journal of medical Internet research (2026). PMID: 41818739 ↗
L1aSR_MA_RCTCited in: Epidemiology and Risk Factors
[32]
Hemeda S, Elmadani M, Merzah M et al.. “Impact of Alcohol Intake on Parkinson's Disease Risk and Progression: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies.” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 41578833 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors
[33]
Yang D, Nepal G, Ojha R et al.. “Association between dairy consumption and Parkinson's disease: A systematic review and meta-analysis.” Public health (2026). PMID: 41544344 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors
[34]
Bang CS, Hasanuzzaman M, Lee JJ et al.. “Association between Helicobacter pylori infection and Parkinson's disease: A systematic review and meta-analysis.” European journal of clinical investigation (2026). PMID: 41527373 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors
[35]
Barer Y, Ast T, Chodick G et al.. “Incretin-based therapy and Parkinson's disease risk among patients with type 2 diabetes: Retrospective cohort study and meta-analysis.” Parkinsonism & related disorders (2026). PMID: 41468681 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors
[36]
Chen X, Barclay NL, Pineda-Moncusí M et al.. “Secular trends of incidence and prevalence of Parkinsonism subtypes: a cohort study in the United Kingdom.” European journal of public health (2026). PMID: 41954920 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Differential Diagnosis, Special Populations
[37]
Bae Y, Song C, Kim S et al.. “Risk of somatoform and sleep-related disorders in Parkinson's disease: A nationwide matched cohort study.” Sleep medicine (2026). PMID: 41812492 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors
[38]
Kamo H, Remz M, Mehta TR et al.. “Five-year risk of cardiovascular events and falling in Parkinson's disease with orthostatic hypotension: A nationwide cohort study.” Parkinsonism & related disorders (2026). PMID: 41637898 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors
[39]
Davoodi L, Frouzanian M, Soleymani E et al.. “Investigating the prevalence of Toxoplasma gondii infection in Parkinson's disease patients and its association with disease severity: a case-control study.” BMC infectious diseases (2026). PMID: 41526839 ↗
L3bCASE_CONTROLCited in: Epidemiology and Risk Factors, Special Populations
[40]
Kang MS, Jung YT, Kim S et al.. “Upper-thoracic predominance and non-vertebral fracture burden in Parkinson's disease: A matched Case-Control study.” Parkinsonism & related disorders (2026). PMID: 41468680 ↗
L3bCASE_CONTROLCited in: Epidemiology and Risk Factors, Special Populations
[41]
Huang X, Cheng Q, Xie Y et al.. “Chinese patent medicine in the treatment of Parkinson's disease: A systematic review and network meta-analysis.” Complementary therapies in clinical practice (2026). PMID: 41505870 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors
[42]
Cheng B, Cheng S, Wei W et al.. “Residential green space, natural environment, domestic garden, and the risk of Parkinson's disease: A prospective cohort study.” Neurobiology of disease (2026). PMID: 41759830 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors
[43]
Gusmão NA, Mateus APM, Oliveira VB et al.. “Parkinson's disease and Porphyromonas gingivalis levels: a case-control study.” Journal of applied oral science : revista FOB (2026). PMID: 41880470 ↗
L3bCASE_CONTROLCited in: Epidemiology and Risk Factors
[44]
Gomes de Luna JR, Lima DP, Gomes VC et al.. “Sarcopenia, body composition, physical performance, and clinical features in Parkinson's disease: a cross-sectional comparative study.” Frontiers in endocrinology (2026). PMID: 41924518 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup
[45]
Zhou L, Guan M, Zhang B et al.. “Depression in Parkinson's disease: prevalence and impact on oculomotor features.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2026). PMID: 41895089 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[46]
Shen Q, Zheng F, Dong Y et al.. “Global, regional, and national burden of Early-onset Parkinson's disease: A comprehensive analysis and forecast, 1990-2021.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41876889 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Special Populations
[47]
Jian X, Yu P, Zhang Y et al.. “Large-scale profiling of blood microbial signatures in patients with Parkinson's disease and its association with disease progression: a cross-sectional study.” EBioMedicine (2026). PMID: 41864063 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[48]
Step K, Ndong Sima CAA, Grant S et al.. “Polygenic risk scores and Parkinson's disease in South Africa advancing ancestry informed disease prediction.” PLoS genetics (2026). PMID: 41801886 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[49]
Ahn SH, Kim DH, Park J et al.. “Dynamic Smoking Patterns and Risk of Parkinson Disease and All-Cause Mortality: A Competing Risk Analysis Approach.” Neurology (2026). PMID: 41740083 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[50]
Tang X, Cui H, Cui H. “Orchestrating the Parkinson's disease microenvironment in 3D for pathogenesis study and therapeutic development.” Biofabrication (2026). PMID: 41719587 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors
[51]
Arias-Carrión O. “Parkinson's Disease: From Gene-Environment Risk to Precision Therapy.” Medical sciences (Basel, Switzerland) (2026). PMID: 41718119 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors
[52]
Onrubia-Márquez M, Garcia MM, Navas F et al.. “MSN Templated with L-Dopa Amide Derivatives Outperforms the Efficiency of Free-L-Dopa in Reducing Parkinson's Behavioral Dysfunction in Mice.” International journal of nanomedicine (2026). PMID: 41710371 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[53]
Li S, Chen S, Yu X et al.. “Scoping review of AI-driven wearable technologies for rehabilitation and functional assessment in Parkinson's disease: a protocol.” BMJ open (2026). PMID: 41692525 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors
[54]
Vakhshoori M, Bondariyan N, Jones J et al.. “The impact of cardiovascular disease on Parkinson's disease: Findings from the PPMI study.” Parkinsonism & related disorders (2026). PMID: 41643580 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[55]
Li G, Li G. “The impact of diabetes mellitus in prodromal Parkinson's disease.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41639475 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[56]
Sun M, Wang X, Lu Z et al.. “GLP-1RAs versus metformin and Parkinson's risk in type 2 diabetes.” Diabetes, obesity & metabolism (2026). PMID: 41582696 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[57]
Di Luca DG, de Havenon A, Prabhune A et al.. “Temporal trends and risk factors of hospital readmission following deep brain stimulation for Parkinson disease.” Parkinsonism & related disorders (2026). PMID: 41579428 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[58]
Mammen JR, Reddy V, Lerner A et al.. “Three years later: tracking bothersome symptoms and impacts for people with early Parkinson's disease.” Journal of neurology (2026). PMID: 41563488 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[59]
Park CW, Choi Y, Sun Y et al.. “Visuospatial dysfunction indicates an increased risk of rapid dementia conversion in Parkinson's disease.” Alzheimer's & dementia : the journal of the Alzheimer's Association (2026). PMID: 41540811 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[60]
Chen W, Du M, Liu M et al.. “Co-occurrence patterns and related risk factors of dementia and Parkinson's disease among older adults across 204 countries and territories: a spatial correspondence and systematic analysis.” BMC medicine (2026). PMID: 41540403 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[61]
Wu J, Zang W, Fang M et al.. “Effects of Wearable Devices on Parkinson Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials Within the International Classification of Functioning, Disability, and Health Framework.” Journal of medical Internet research (2026). PMID: 41849761 ↗
L1aSR_MA_RCTCited in: Diagnosis and Workup
[62]
Alla D, Shah D, Ramsundar R et al.. “Efficacy and Safety of Deferiprone for Parkinson's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” Clinical neuropharmacology (Unknown). PMID: 41790482 ↗
L1aSR_MA_RCTCited in: Diagnosis and Workup
[63]
Srp M, Hoskovcova M, Lagnerova R et al.. “Enhancing Adherence to Home-Based Expiratory Muscle Strength Training in Parkinson Disease: Randomized Controlled Trial of an mHealth Intervention.” Journal of medical Internet research (2026). PMID: 41812147 ↗
L1bRCTCited in: Diagnosis and Workup, Management, Supportive Care and Complication Management
[64]
Raza H, Nizam B, Padaniya A et al.. “Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta-Analysis.” Brain and behavior (2026). PMID: 41880197 ↗
L2aSR_OBSCited in: Diagnosis and Workup
[65]
Mohammed I, Nankya Y, Hong UT et al.. “The role of N-acetylcysteine and glutathione in the management of Parkinson's disease: a systematic review of oxidative biomarkers and clinical outcomes.” Amino acids (2026). PMID: 41874704 ↗
L2aSR_OBSCited in: Diagnosis and Workup
[66]
Boffino CC, Holzhacker TY, Silva SMA et al.. “Effects of galvanic vestibular stimulation on motor control in patients with Parkinson's disease: study protocol.” Arquivos de neuro-psiquiatria (2026). PMID: 41759503 ↗
L2bTRIAL_NONRANDOMCited in: Diagnosis and Workup, Management
[67]
Brito SAF, Scianni AA, Silveira BMF et al.. “High-intensity respiratory muscle training improves maximal respiratory pressures, breathing endurance, dyspnoea and exercise capacity in people with Parkinson's disease: a randomised trial.” Journal of physiotherapy (2026). PMID: 41933952 ↗
L1bRCTCited in: Diagnosis and Workup, Differential Diagnosis, Management, Supportive Care and Complication Management
[68]
Coskun K, Turan GB. “The Effects of Color Therapy on Fatigue, Depression, and Quality of Life in Parkinson's Patients: A Randomized Controlled Trial.” Brain and behavior (2026). PMID: 41888497 ↗
L1bRCTCited in: Diagnosis and Workup, Management
[69]
Baggen RJ, Van Bladel A, Prins MR et al.. “Visual perturbation training to reduce visual dependency in Parkinson's disease: A randomized controlled trial.” PloS one (2026). PMID: 41770816 ↗
L1bRCTCited in: Diagnosis and Workup, Management
[70]
Huang H, Zhu R, Zheng Y et al.. “Effect evaluation of the positive emotion, engagement, relationships, meaning, and accomplishment (PERMA) positive psychological intervention model in patients with Parkinson's disease.” Neuropsychology (2026). PMID: 41770127 ↗
L1bRCTCited in: Diagnosis and Workup
[71]
Lonczewski S, Bader V, Ortmann L et al.. “A Novel 3D Semi-Automated Full Quantification Technique for Detection of Intraneural Phospho-α-Synuclein in Skin Biopsies.” European journal of neurology (2026). PMID: 41995607 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis, Special Populations
[72]
Sowalsky KL, Okun MS, Terza M et al.. “Regular Metronome, Fractal Metronome, and Music for Parkinson Gait.” JAMA network open (2026). PMID: 41989783 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis, Management
[73]
Kim YJ, Choi SI, Yang H et al.. “Insole-Derived Plantar Pressure Variability Reveals Dual-Task Gait Differences in Early-Stage Parkinson's Disease.” IEEE journal of translational engineering in health and medicine (2026). PMID: 41970941 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis, Special Populations
[74]
Yu Q, Zhang Y, Huang P et al.. “Midbrain Energy Homeostasis Biomarker for Differential Diagnosis of Early-Stage Parkinson Disease: A 1H and 31P MRI Study.” Radiology (2026). PMID: 41944724 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis
[75]
Zhu S, Yi W, Feng Y et al.. “Decomposed Transfer Entropy for EEG Brain Networks: Parkinson's Disease and Dopaminergic Modulation.” IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society (2026). PMID: 41941809 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis
[76]
Akram SW, K C. “Enhancing Parkinson's Disease Staging: An Integrative Deep Learning Framework for Multimodal Feature Selection.” Journal of molecular neuroscience : MN (2026). PMID: 41910849 ↗
L5OTHERCited in: Diagnosis and Workup
[77]
Lin J, Lee PY, Tran KKN et al.. “Detailed Outer Retinal Assessment in Parkinson's Disease Using Directional OCT.” Investigative ophthalmology & visual science (2026). PMID: 41910525 ↗
L5OTHERCited in: Diagnosis and Workup
[78]
Noor MS, Jadapalli J, Walker HC et al.. “Localizing beta synchronous neurons in the STN using directional DBS recordings and patient-specific biophysical models.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2026). PMID: 41881902 ↗
L5OTHERCited in: Diagnosis and Workup, Management
[79]
Boebinger SE, Payne AM, Xiao J et al.. “Cortically Mediated Muscle Responses to Balance Perturbations Increase with Perturbation Magnitude in Older Adults with and without Parkinson's Disease.” eNeuro (2026). PMID: 41871956 ↗
L5OTHERCited in: Diagnosis and Workup
[80]
Li Z, Yang R, Cui X et al.. “Orthostatic blood pressure trajectories characterize heterogeneous disease progression in Parkinson's disease.” Journal of neurology (2026). PMID: 41870682 ↗
L5OTHERCited in: Diagnosis and Workup
[81]
Niemi KJ, Jaakkola E, Myller EM et al.. “Striatal Dopamine Transporter and Rest Tremor in Parkinson Disease: A Clinical Validation.” Neurology (2026). PMID: 41855450 ↗
L5OTHERCited in: Diagnosis and Workup
[82]
Wang Q, Lv M, Zhou X et al.. “Association of choroid plexus volume with MRI indices of DTI-derived parameters and perivascular spaces in patients with neurodegenerative diseases.” European journal of radiology (2026). PMID: 41849872 ↗
L5OTHERCited in: Diagnosis and Workup, Special Populations
[83]
Morcillo-Martínez L, Sanz-Mármol M, Romanos-Navarrete AI et al.. “Effects of a level-based immersive virtual reality physical therapy program on static and dynamic balance in Parkinson's disease: Protocol for a randomized controlled trial.” PloS one (2026). PMID: 41838745 ↗
L2bTRIAL_NONRANDOMCited in: Diagnosis and Workup, Management, Special Populations
[84]
Wei X, Tian Y, Lu Q et al.. “Dynamic Reconfiguration of Cognitive Networks and Recovery From Microlesion Effects in Parkinson's Disease: Insights From a Longitudinal fNIRS Study.” CNS neuroscience & therapeutics (2026). PMID: 41834033 ↗
L5OTHERCited in: Diagnosis and Workup, Management
[85]
Gravel P, Gallezot JD, Fontaine K et al.. “Variance reduction with synaptic density imaging in Parkinson's disease using direct-4D PET image reconstruction.” Physics in medicine and biology (2026). PMID: 41825140 ↗
L5OTHERCited in: Diagnosis and Workup
[86]
Mezzini A, Kumar S, Sharrad S et al.. “The Topographical, Sensory, and Temporal Characteristics of Pain in Parkinson's Disease: A Cross-Sectional Survey.” Pain practice : the official journal of World Institute of Pain (2026). PMID: 41814463 ↗
L5OTHERCited in: Diagnosis and Workup, Special Populations
[87]
Kassubek J, Höglinger GU, Zůza A et al.. “Hypothalamic atrophy in progressive supranuclear palsy, assessed by convolutional neural network-based automatic segmentation.” Journal of neurology (2026). PMID: 41811373 ↗
L5OTHERCited in: Diagnosis and Workup
[88]
Jiang H, Chen G, Ma J et al.. “Precise estimation of tissue microstructure with hybrid graph transformer.” Artificial intelligence in medicine (2026). PMID: 41806520 ↗
L5OTHERCited in: Diagnosis and Workup
[89]
Mîndreanu R, Chiș IC, Sevastre-Berghian A et al.. “N-Acetylcysteine in Neurological Disorders: A Systematic Review of Clinical and Translational Evidence Across Seven Disorders.” International journal of molecular sciences (2026). PMID: 41977262 ↗
L2aSR_OBSCited in: Differential Diagnosis
[90]
Del Papa DF, Herman J, Kunju AT et al.. “Neurovascular Unit Dysfunction and Cerebral Small Vessel Disease in Parkinson Disease: A Systematic Review and a Meta Analysis.” Neurology (2026). PMID: 41955557 ↗
L2aSR_OBSCited in: Differential Diagnosis, Guidelines and Resources
[91]
Hu S, Lei J, You HJ. “Exercise for Non-Motor Symptoms of Parkinson's Disease: An Evidence-Based Review of Clinical Trials, Dosing Considerations, and Mechanistic Insights.” Neural plasticity (2026). PMID: 41918452 ↗
L2bTRIAL_NONRANDOMCited in: Differential Diagnosis, Management, Supportive Care and Complication Management
[92]
de Ronde EM, Birnie E, Rijpma A et al.. “Individualised stimlation parameters in deep brain stimulation for Parkinson's disease based on disease phenotype and brain connectivity: protocol for a randomised feasibility study in a tertiary care centre (iDBS trial).” BMJ open (2026). PMID: 41974545 ↗
L2bTRIAL_NONRANDOMCited in: Differential Diagnosis, Management
[93]
Zhu Y, Zhao L, Li Y et al.. “Disruption of Synaptic Vesicle Trafficking in Alzheimer's and Parkinson's Disease: Mechanisms and Therapeutic Implication.” International journal of molecular sciences (2026). PMID: 41977275 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis
[94]
Musarò D, Greco M, Lanza M et al.. “Copper Dyshomeostasis Affects α-Synuclein Clearance Mechanisms in Parkinson's Disease: Insights from In Vitro Models and Translational Evidence.” International journal of molecular sciences (2026). PMID: 41977181 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis
[95]
Almeida V, Herz DM, Blech J et al.. “Cognitive trajectories in Parkinson's disease patients, a review on the impact of subthalamic deep brain stimulation (STN-DBS) and emerging adaptive strategies.” Translational psychiatry (2026). PMID: 41963290 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis, Management
[96]
Ramanan S, Johnson GVW. “A Bioinformatic Analysis of BAG Protein Interactors and Pathways in Alzheimer's and Parkinson's Disease.” Journal of molecular neuroscience : MN (2026). PMID: 41925793 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis
[97]
Yin X, Wang C, Lin W et al.. “Nanotherapeutic Interventions for Parkinson's Disease: Modulating Pathogenic Mechanisms and Overcoming Therapeutic Obstacles.” International journal of nanomedicine (2026). PMID: 41907367 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis, Management
[98]
Ozkaya KS, Browning KN. “The Brain-Gut Axis in Parkinson's Disease Pathology.” Comprehensive Physiology (2026). PMID: 41905903 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis
[99]
Aslan FS, Barut B, Ozturk S et al.. “Neurotransmitter Dysregulation in Parkinson's Disease: Pathophysiological Insights and Therapeutic Perspectives.” ACS chemical neuroscience (2026). PMID: 41904982 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis
[100]
Davis A, Casmedes IY, Burton MD. “Radical Revelations: The Interplay of Nitrosative Stress, the Endocannabinoid System, and Treatment of Age-Related Disorders.” International journal of molecular sciences (2026). PMID: 41898672 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis
[101]
Rojas Romero CJ, Guerrero Y. “Singing-Based Interventions for Treating Hypokinetic Dysarthria in Parkinson's Disease: A Systematic Review.” Journal of music therapy (2026). PMID: 41990042 ↗
L2aSR_OBSCited in: Differential Diagnosis, Management
[102]
Garanin AA, Aydumova OY, Rubanenko AO et al.. “[Speech signal acoustic analysis in the diagnosis of neurological and mental diseases: a systematic review and meta-analysis].” Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2026). PMID: 41984552 ↗
L2aSR_OBSCited in: Differential Diagnosis
[103]
Jin J, Jiang Y, Zhou Y et al.. “AI-Enabled Flexible Sensing Ecosystems for Parkinson's Disease: Advancing Digital Biomarkers and Closed-Loop Interventions.” Sensors (Basel, Switzerland) (2026). PMID: 41977856 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis
[104]
Singhal M, Grannie C, Burnette M et al.. “Freezing of Gait in Parkinson's Disease: A Scoping Review on the Path Towards Real-Time Therapies.” Sensors (Basel, Switzerland) (2026). PMID: 41977827 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis
[105]
Shi WQ, Zhuang JH, Zhang QH et al.. “Synthesis and Biological Evaluation of RBG Derivatives as Nrf2 Activators for the Treatment of Parkinson's Disease.” International journal of molecular sciences (2026). PMID: 41977502 ↗
L5OTHERCited in: Differential Diagnosis
[106]
Toledano-Pinedo M, Porro-Pérez A, Schäker-Hübner L et al.. “Polyfunctionalized N-Arylsulfonyl Indoles: Identification of (E)-N-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1H-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-Based Therapy of Parkinson's Disease.” International journal of molecular sciences (2026). PMID: 41977320 ↗
L5OTHERCited in: Differential Diagnosis
[107]
Yang JC, Situ J, Troutman R et al.. “A microbiome quantitative trait locus in SLC39A8 modulates disease severity in synucleinopathy-induced models of Parkinson's disease.” Human molecular genetics (2026). PMID: 41955304 ↗
L5OTHERCited in: Differential Diagnosis
[108]
Yang D, Xu J, Zhu Y et al.. “The genetic associations of DNAJC family members with Parkinson's disease: comprehensive evidence from burden analysis and Mendelian randomization.” Human genetics (2026). PMID: 41951985 ↗
L5OTHERCited in: Differential Diagnosis
[109]
Gowied HG, El-Mezayen NS, Afify EA. “Valsartan promotes neuroprotection in Parkinson's disease via epigenetic modulation and activation of the ASCL1/Nurr1 pathway.” Life sciences (2026). PMID: 41936814 ↗
L5OTHERCited in: Differential Diagnosis
[110]
Ahumada-Montalva P, Muñoz-Carvajal F, Bórquez-Macaya S et al.. “TMBIM6 enhances dopaminergic neuron survival by modulating the IRE1a pathway in Parkinson's disease.” Cell death & disease (2026). PMID: 41932887 ↗
L5OTHERCited in: Differential Diagnosis
[111]
Liu C, Jin Y, Lin H et al.. “Effects of transcutaneous auricular vagus nerve stimulation on motor and gait performance in Parkinson's disease: a meta-analysis of randomized controlled trials.” Journal of neurology (2026). PMID: 41805933 ↗
L1aSR_MA_RCTCited in: Management, Supportive Care and Complication Management
[112]
Jun JS, Kang N, Park K et al.. “Cycling exercise for autonomic symptoms in early Parkinson's disease.” Autonomic neuroscience : basic & clinical (2026). PMID: 41740291 ↗
L1bRCTCited in: Management, Supportive Care and Complication Management
[113]
Fidan C. “Technologies used in Parkinson's disease: a meta-analysis of their effect on health-related quality of life.” Journal of neurology (2026). PMID: 41817821 ↗
L2aSR_OBSCited in: Management
[114]
Zhang X, Zheng L, Li Y et al.. “Efficacy of rTMS and TBS on the motor symptoms in Parkinson's disease: a network meta-analysis.” Journal of neurology (2026). PMID: 41817817 ↗
L2aSR_OBSCited in: Management
[115]
Senthilkumar S, S M, Rizvi MF et al.. “Deep brain stimulation beyond Motor control: A systematic review and meta-analysis of sleep outcomes in Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41702753 ↗
L2aSR_OBSCited in: Management
[116]
van der Linden C, Berger T, Dembek TA et al.. “Tractography-guided versus clinical contact selection for deep brain stimulation in tremor - A prospective clinical trial.” Brain stimulation (2026). PMID: 41740836 ↗
L2bTRIAL_NONRANDOMCited in: Management
[117]
Zhang R, Feng R, Wang J et al.. “Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson's disease: a randomized phase 2 trial.” Signal transduction and targeted therapy (2026). PMID: 41826284 ↗
L1bRCTCited in: Management
[118]
Ferrara PE, Della Casa E, Calciano R et al.. “Effects of Focal Muscle Vibration on Static and Dynamic Balance in Patients with Parkinson's Disease: Preliminary Results of a Retrospective Study.” Medicina (Kaunas, Lithuania) (2026). PMID: 41752699 ↗
L2bCOHORTCited in: Management
[119]
Hu W, Li Y, Yang A et al.. “Research progress on employing medicinal plants and their active compounds to target autophagic pathways for Parkinson's disease therapy.” Journal of ethnopharmacology (2026). PMID: 41895540 ↗
L2aSR_OBSCited in: Management
[120]
Pinheiro RSA, Silva Júnior HBD, Guimarães BB et al.. “Effects of Transcranial Direct Current Stimulation on Speech and Voice Changes in Parkinson's Disease: a Systematic Review with Meta-Analysis.” CoDAS (2026). PMID: 41779498 ↗
L2aSR_OBSCited in: Management
[121]
Busot D, Yang H, Sawmiller D et al.. “The Progress of Active Immunotherapy for Parkinson's Disease.” International journal of molecular sciences (2026). PMID: 41828418 ↗
L5REVIEW_NARRATIVECited in: Management
[122]
Jost ST, Atwani C, Loehrer PA et al.. “Patients with symmetric Parkinson's disease do poorly with subthalamic stimulation.” Journal of neurology, neurosurgery, and psychiatry (2026). PMID: 41781214 ↗
L5OTHERCited in: Management
[123]
Li J, Liu T, Wei J. “Exercise as Chronotherapy: Regulating Circadian Rhythms to Alleviate Symptoms in Parkinson's Disease.” ACS chemical neuroscience (2026). PMID: 41766127 ↗
L5REVIEW_NARRATIVECited in: Management
[124]
Rajyasree A, Balamurugan J. “"Every day is a battle against Parkinson's"-a qualitative study on older adults at the long-term care facilities in Chennai.” Frontiers in public health (2026). PMID: 41756082 ↗
L5OTHERCited in: Management, Special Populations
[125]
Qiu S, Wei Y, Gao C et al.. “Effects of combined transcranial direct current stimulation and gait training in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.” Systematic reviews (2025). PMID: 41053827 ↗
L1aSR_MA_RCTCited in: Supportive Care and Complication Management
[126]
Lima JL, Inacio PA, Sá Filho A et al.. “Effectiveness of virtual reality rehabilitation with exergames on functional rehabilitation in Parkinson's disease: a systematic review of chronic randomized controlled trials.” Expert review of neurotherapeutics (2025). PMID: 40963232 ↗
L1aSR_MA_RCTCited in: Supportive Care and Complication Management
[127]
Madrid J, Batzianouli E, Rutz D et al.. “Can transcranial Direct Current Stimulation enhance the efficacy of a rehabilitative intervention for the treatment of Freezing of Gait in Parkinson's disease? A double-blind, randomized controlled study.” Journal of Parkinson's disease (2026). PMID: 41637203 ↗
L1bRCTCited in: Supportive Care and Complication Management
[128]
Matsushita W, Nagaki K, Takashi N et al.. “Feasibility and potential effectiveness of an exergame program for people with moderate to advanced Parkinson's disease: A pilot randomized controlled trial.” Journal of Parkinson's disease (2026). PMID: 41637155 ↗
L1bRCTCited in: Supportive Care and Complication Management
[129]
Villamil-Cabello E, Molinero-Martín E, Luque-Casado A et al.. “Home-Based time-constrained reactive training enhances movement speed in upper and lower limbs in Parkinson's disease: A randomized controlled trial.” Journal of Parkinson's disease (2026). PMID: 41615860 ↗
L1bRCTCited in: Supportive Care and Complication Management
[130]
Eldemir S, Polat EA, Gokdogan CM et al.. “The effect of rebound therapy in Parkinson's disease: A single-blinded randomized controlled trial.” Gait & posture (2026). PMID: 41592453 ↗
L1bRCTCited in: Supportive Care and Complication Management, Special Populations
[131]
Wang R, Liu M, Liu Q et al.. “Home-based transcutaneous auricular vagus nerve stimulation (taVNS) improves motor and non-motor symptoms by improving autonomic and brain functions in patients with Parkinson's disease: A randomized clinical trial.” Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2026). PMID: 41549029 ↗
L1bRCTCited in: Supportive Care and Complication Management
[132]
Kalva-Filho CA, Zampier VC, Orcioli-Silva D et al.. “Inter-effort recovery hypoxia did not mitigate acute treadmill effects in people with Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41389475 ↗
L1bRCTCited in: Supportive Care and Complication Management
[133]
Rascol O, Ory-Magne F, Meissner WG et al.. “Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa-Therapy in Parkinson's Disease: A Randomized, Placebo-Controlled Study (PREMANDYSK).” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 41316871 ↗
L1bRCTCited in: Supportive Care and Complication Management
[134]
da Conceição NR, Vitório R, Morya E et al.. “Effect of Dynamic Balance Training Combined with Different Intensities of Cerebellar Transcranial Direct Current Stimulation in People with Parkinson's Disease: a Randomized Clinical Trial.” Cerebellum (London, England) (2025). PMID: 41239034 ↗
L1bRCTCited in: Supportive Care and Complication Management
[135]
Topal A, Durmaz Çelik N, Ayık B et al.. “Effect of a Wearable Sensor-Based Posture Correction Brace on Static Balance and Posture in Parkinson's Disease.” American journal of physical medicine & rehabilitation (2026). PMID: 41082253 ↗
L1bRCTCited in: Supportive Care and Complication Management
[136]
Thanakamchokchai J, Ajjimaporn A, Richards J et al.. “High-frequency rTMS and home-based exercise in individuals with Parkinson's disease: A double-blind randomized controlled trial.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2025). PMID: 40934835 ↗
L1bRCTCited in: Supportive Care and Complication Management
[137]
Hernandez-Martinez J, Branco BHM, Cid-Calfucura I et al.. “Exergaming Compared to Conventional Physical Exercise Interventions on Health Status in Older People with Parkinson's Disease: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.” Medicina (Kaunas, Lithuania) (2025). PMID: 41303837 ↗
L1aSR_MA_RCTCited in: Supportive Care and Complication Management
[138]
Mollinedo-Cardalda I, Monge-Pereira E, Pereira-Pedro KP et al.. “Acute effects of an aerobic dual task on processing speed and attention in Parkinson's disease: a randomised controlled trial study.” Journal of bodywork and movement therapies (2025). PMID: 41316559 ↗
L1bRCTCited in: Supportive Care and Complication Management
[139]
Li Y, Liu Y, Lin Z et al.. “Aerobic exercise modulates plasma oxidized lipid metabolites and neurotransmitters in Parkinson's disease motor subtypes.” Brain research (2025). PMID: 41205731 ↗
L1bRCTCited in: Supportive Care and Complication Management
[140]
Zeng B, Wang H, Chen J et al.. “Optimal exercise modalities and doses for improving quality of life in patients with Parkinson's disease: a network meta-analysis and dose-response study.” Journal of neurology (2026). PMID: 41656425 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management
[141]
Yan HL, Li MM. “Effects of exercise modalities on cognitive function and depression in patients with Parkinson's disease: A systematic review and network meta-analysis.” Geriatric nursing (New York, N.Y.) (2025). PMID: 41129905 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management
[142]
Han C, Zhang H, Wang Q et al.. “Physical exercise and inflammation in Parkinson's disease: a review.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 41085917 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management
[143]
Decaix T, Bonnin C, Götze K et al.. “Benefits of physical activity on cognitive function in patients with neurocognitive disorders: A systematic review.” The Journal of frailty & aging (2025). PMID: 40911419 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management
[144]
Xiao C, Zhou F. “Yi Jin Jing Exercise Program Improves in Cognition, Sleep and Functional Mobility for Mild and Moderate Parkinson 's Disease: A Randomized Controlled Trial.” Experimental aging research (2026). PMID: 41388828 ↗
L1bRCTCited in: Supportive Care and Complication Management
[145]
Fukuchi CA, Moreno VC, Kalva-Filho CA et al.. “Combining automated mechanical peripheral stimulation and treadmill exercise for gait rehabilitation in Parkinson's disease: A randomized controlled trial.” Clinical biomechanics (Bristol, Avon) (2026). PMID: 41337903 ↗
L1bRCTCited in: Supportive Care and Complication Management
[146]
González-García P, Heredia-Rizo AM, Garrido-Bueno A et al.. “Multi-Session whole body vibration program on Parkinson's disease symptoms: Systematic review and meta-analysis.” Journal of bodywork and movement therapies (2025). PMID: 41316661 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management
[147]
Domínguez-Pera I, Lucena-Anton D, Estebanez-Perez MJ et al.. “Efficacy of transcranial direct current stimulation combined with gait training in patients with Parkinson's disease: Systematic review and meta-analysis.” CNS spectrums (2025). PMID: 41065007 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management
[148]
Taveira RS, Vasconcellos LS, Bezerra CF et al.. “Telerehabilitation for people with Parkinson's disease: protocol of a randomised clinical trial of mixed methods.” BMJ open (2025). PMID: 41320221 ↗
L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management
[149]
Tufft A, Neilens H, Marsden J et al.. “Efficacy of peroneal nerve functional electrical stimulation (FES) for the reduction of bradykinesia in Parkinson's disease: an assessor-blinded randomised controlled trial (STEPS II)-study protocol.” BMJ open (2025). PMID: 40912703 ↗
L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management
[150]
Greenland JC, Dresser K, Cutting E et al.. “Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.” The Lancet. Neurology (2026). PMID: 41389828 ↗
L1bRCTCited in: Special Populations
[151]
Song T, Xiang L, Liu Y et al.. “Survival and related factors in patients with Parkinson's disease: a multicenter prospective cohort study in China.” Journal of neurology (2026). PMID: 41507598 ↗
L2bCOHORTCited in: Special Populations
[152]
Fleet JL, Carter B, Cadarette SM et al.. “Fracture incidence and osteoporosis treatment in Parkinson's disease: a population-based cohort study.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026). PMID: 41369770 ↗
L2bCOHORTCited in: Special Populations
[153]
Erfmann K, Hirschwald J, Hofacker J et al.. “Characteristics of Swallowing Function in People with Parkinson's Disease: A Scoping Review.” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 41508417 ↗
L5REVIEW_NARRATIVECited in: Special Populations
[154]
Hickman J, Tsai A, Fullard M et al.. “Early-Onset Parkinson's Disease: Unique Features and Management Approaches.” Current neurology and neuroscience reports (2025). PMID: 41410819 ↗
L5REVIEW_NARRATIVECited in: Special Populations
[155]
Calzada García M, Ayala A, Navarta Sánchez MV et al.. “[Impact of a community-based multisectoral intervention on the health of individuals with parkinson's disease and their family caregivers].” Semergen (2026). PMID: 41707402 ↗
L1bRCTCited in: Special Populations
[156]
Machane D, Shaji MS, Borchman D et al.. “Meibum Lipid Saturation Related to Dry Eye, Age, and Sex Using Nuclear Magnetic Resonance Spectroscopy.” Investigative ophthalmology & visual science (2026). PMID: 41910524 ↗
L5OTHERCited in: Special Populations
[157]
Sriram D, Pourzinal D, Bailey DX et al.. “Recommendations to Improve Healthcare Service Provision for Cognitive Impairment in People With Parkinson's Disease: A Mixed Methods Study of the Lived Experience Expert Perspective.” Health expectations : an international journal of public participation in health care and health policy (2026). PMID: 41834361 ↗
L5OTHERCited in: Special Populations, Guidelines and Resources
[158]
Hatakeyama S, Miki Y, Tanaka MT et al.. “Cerebrospinal fluid HOMER1 and NPTX2 as candidate signatures in early-stage multiple system atrophy-parkinsonism.” Journal of the neurological sciences (2026). PMID: 41780424 ↗
L5OTHERCited in: Special Populations
[159]
Lian J, Fan Z, Petrazzini BO et al.. “Subtyping Alzheimer's disease and Parkinson's disease using longitudinal electronic health records.” Nature aging (2026). PMID: 41748957 ↗
L5OTHERCited in: Special Populations
[160]
Falk L, Brunius C, Crnic Bojkovic T et al.. “A data-driven SSM/PCA analysis approach for differential diagnosis of parkinsonism using 11C-PE2I PET.” NeuroImage. Clinical (2026). PMID: 41719754 ↗
L5OTHERCited in: Special Populations
[161]
Bolsewig K, Bellomo G, Hok-A-Hin YS et al.. “A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders.” Nature medicine (2026). PMID: 41699128 ↗
L5OTHERCited in: Special Populations
[162]
Anis S, Kundrick A, Callegari Piccinin C et al.. “Phosphorylated alpha-synuclein skin biopsy alters diagnosis in two out of three patients: Initial findings in a tertiary center.” Parkinsonism & related disorders (2026). PMID: 41691977 ↗
L5OTHERCited in: Special Populations
[163]
Ou C, Chen B, Yu H et al.. “Association between the triglyceride-glucose frailty index and Parkinson's disease in middle-aged and older adults: a comparative cross-national analysis of NHANES and CHARLS.” Parkinsonism & related disorders (2026). PMID: 41691976 ↗
L5OTHERCited in: Special Populations
[164]
Kim D, Tjaden K, Stipancic KL et al.. “Variable Speech Cueing Effects in Talkers With Parkinson's Disease.” American journal of speech-language pathology (2026). PMID: 41666082 ↗
L5OTHERCited in: Special Populations
[165]
Gunawardana CW, Burke PGR, Ignatavicius A et al.. “Comparing phenotypic features between Parkinson's disease dementia and dementia with Lewy bodies.” Journal of neurology (2026). PMID: 41665721 ↗
L5OTHERCited in: Special Populations
[166]
Singovski S, Harlé L, Zerbit J et al.. “Continuous subcutaneous apomorphine infusion to improve comfort in advanced degenerative Parkinsonian syndrome patients: a retrospective descriptive study in a home-based setting.” Parkinsonism & related disorders (2026). PMID: 41653908 ↗
L5OTHERCited in: Special Populations
[167]
Hobson R, Levy SHS, Singal CMS et al.. “Clonal CD8+ T cells populate the leptomeninges and coordinate with immune cells in human degenerative brain diseases.” Nature immunology (2026). PMID: 41593242 ↗
L5OTHERCited in: Special Populations
[168]
Pourzinal D, Brooks D, Sriram D et al.. “Best practice guidelines for the diagnosis, evaluation, and management of cognitive disorders in Parkinson's disease.” Age and ageing (2026). PMID: 41870152 ↗
L1cGUIDELINECited in: Guidelines and Resources
[169]
Fanciulli A, Sixel-Döring F, Buhmann C et al.. “Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.” Journal of neurology (2025). PMID: 39751950 ↗
L1cGUIDELINECited in: Guidelines and Resources
[170]
Vieira SRL, Mezabrovschi R, Toffoli M et al.. “Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease.” Movement disorders : official journal of the Movement Disorder Society (2024). PMID: 39258449 ↗
L1cGUIDELINECited in: Guidelines and Resources
[171]
Witt K, Levin J, van Eimeren T et al.. “Diagnostics and treatment of impulse control disorders, psychosis and delirium: systemic review-based recommendations - guideline "Parkinson's disease" of the German Society of Neurology.” Journal of neurology (2024). PMID: 39046524 ↗
L1cGUIDELINECited in: Guidelines and Resources
[172]
Tönges L, Buhmann C, Eggers C et al.. “Guideline "Parkinson's disease" of the German Society of Neurology (Deutsche Gesellschaft für Neurologie): concepts of care.” Journal of neurology (2024). PMID: 38969876 ↗
L1cGUIDELINECited in: Guidelines and Resources
[173]
Walter U, Loewenbrück KF, Dodel R et al.. “Systematic review-based guideline "Parkinson's disease" of the German Society of Neurology: diagnostic use of transcranial sonography.” Journal of neurology (2024). PMID: 38963440 ↗
L1cGUIDELINECited in: Guidelines and Resources
[174]
Ó Breasail M, Singh KP, Lithander FE et al.. “Management of Osteoporosis in Parkinson's Disease: A Systematic Review of Clinical Practice Guidelines.” Movement disorders clinical practice (2025). PMID: 39704021 ↗
L1cGUIDELINECited in: Guidelines and Resources
[175]
Maia DP, Cury RG, Brandão PRP et al.. “Guidelines for Parkinson's disease management part II: consensus from the movement disorders scientific department of the Brazilian Academy of Neurology - non-motor symptoms.” Arquivos de neuro-psiquiatria (2025). PMID: 39993447 ↗
L1cGUIDELINECited in: Guidelines and Resources
[176]
Liao J, Wang L, Liu R et al.. “Altered regional spontaneous brain activity in Parkinson's disease: a meta-analysis.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41579202 ↗
L2aSR_OBSCited in: Guidelines and Resources
[177]
Li S, Yang C, Wu J et al.. “Cerebrospinal fluid biomarkers for diagnosis of Parkinson's disease: a systematic review and network meta-analysis.” Journal of neurology (2025). PMID: 41324773 ↗
L2aSR_OBSCited in: Guidelines and Resources
[178]
Garon M, Weck C, Leta V et al.. “Early thinking palliative care for people with Parkinson's disease: A thematic synthesis based on a systematic mixed-methods review.” Journal of Parkinson's disease (2025). PMID: 40320755 ↗
L2aSR_OBSCited in: Guidelines and Resources
[179]
Guidetti M, Marceglia S, Bocci T et al.. “Is physical therapy recommended for people with parkinson's disease treated with subthalamic deep brain stimulation? a delphi consensus study.” Journal of neuroengineering and rehabilitation (2025). PMID: 40211348 ↗
L2aSR_OBSCited in: Guidelines and Resources
[180]
Rosado-Martins F, Santos B, Costa CM et al.. “Vestibular Dysfunction in Parkinson's Disease: A Systematic Review of Signs and Symptoms.” Movement disorders clinical practice (2026). PMID: 40854008 ↗
L2aSR_OBSCited in: Guidelines and Resources
[181]
Veilleux Carpentier A, Malaty IA, LeWitt PA et al.. “A Systematic Review of the Parkinson's Foundation Hospital Care Recommendations.” Movement disorders clinical practice (2026). PMID: 40736219 ↗
L2aSR_OBSCited in: Guidelines and Resources
[182]
Lima DP, Gomes VC, Luna JRG et al.. “Assessment of sarcopenia tools as predictors of falls in patients with mild to moderate Parkinson's Disease: A cohort study.” Clinics (Sao Paulo, Brazil) (2025). PMID: 40972508 ↗
L2bCOHORTCited in: Guidelines and Resources
[183]
Cordillet S, Drapier S, Leh F et al.. “Detecting Freezing of Gait in Parkinson Disease Using Multiple Wearable Sensors Sets During Various Walking Tasks Relative to Medication Conditions (DetectFoG): Protocol for a Prospective Cohort Study.” JMIR research protocols (2025). PMID: 39913915 ↗
L2bTRIAL_NONRANDOMCited in: Guidelines and Resources
[184]
Gülke E, Lewis SJG. “What is new in Freezing of Gait?” Journal of neurology (2026). PMID: 41865085 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources
[185]
Chen K, Hao W, Ji Y et al.. “Two novel iron metabolism-related genes identified as diagnostic indicators in substantia nigra of patients with Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41643581 ↗
L5OTHERCited in: Guidelines and Resources
[186]
Anis S, Clark PA, Shaffer S et al.. “Introducing a workflow algorithm for adaptive DBS programming in Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41577516 ↗
L5OTHERCited in: Guidelines and Resources
[187]
Safarpour D, Brooks A, Smiley A et al.. “Consensus expert recommendations for management of dysphagia during hospital admission in Parkinson's disease.” Journal of Parkinson's disease (2026). PMID: 41490026 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources
[188]
Pedrosa AJ, Molter JN, Brito de Almeida L et al.. “A modified Delphi study of post-operative management for subthalamic deep brain stimulation in Parkinson's disease.” Journal of Parkinson's disease (2026). PMID: 41217788 ↗
L5OTHERCited in: Guidelines and Resources
[189]
Rosenbohm A, Nguyen-Younossi N, Kassubek J. “Parkinson's disease-associated camptocormia: biopsy-confirmed focal myositis and treatment options.” Journal of neurology (2025). PMID: 41131373 ↗
L5OTHERCited in: Guidelines and Resources
[190]
Houston E, Boyd S, Iyer V et al.. “The need for developing consensus-based guidelines in assessing Parkinson's disease laterality.” Parkinsonism & related disorders (2025). PMID: 41039696 ↗
L5OTHERCited in: Guidelines and Resources
[191]
Poplawska-Domaszewicz K, Kaasinen V, van der Plas AA et al.. “Management of neuropsychiatric, motor and non-motor symptoms in Parkinson´s disease after long distance air travel: a consensus view.” Journal of neural transmission (Vienna, Austria : 1996) (2025). PMID: 40986033 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources
[192]
Sajin V, Goodall M, Macerollo A. “Camptocormia in Parkinson's disease: state of the art and future directions.” Journal of neurology (2025). PMID: 40975851 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources
[193]
Wang S, Zhou F, Fang X et al.. “Evidence-based summary of the prevention and management of constipation in patients with Parkinson's disease.” Geriatric nursing (New York, N.Y.) (2025). PMID: 40834448 ↗
L5OTHERCited in: Guidelines and Resources
[194]
Middlebrooks EH, Bot M, Patriat R et al.. “Multi-institutional recommendations on the use of 7T MRI in deep brain stimulation.” Journal of neurosurgery (2025). PMID: 40614283 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources
[195]
Esper CD, Hogan KN, Abeysekara P et al.. “Case Definitions and Data Sources for NNCSS Parkinson Disease Surveillance: A Systematic Review.” JAMA network open (2026). PMID: 42258214 ↗
L2aCited in: Definition, Synonyms, and Classification
[196]
Delva A, Fereshtehnejad SM, Vo A et al.. “Evolution of Motor and Nonmotor Characteristics in an Idiopathic/Isolated REM Sleep Behavior Disorder Cohort.” Neurology (2025). PMID: 40921020 ↗
L4Cited in: Definition, Synonyms, and Classification
[197]
Mana M, Mana J, Stofanikova P et al.. “Evaluation of diagnostic concordance between algorithms for Parkinson's disease dementia.” Journal of Parkinson's disease (2026). PMID: 42277619 ↗
L3bCited in: Definition, Synonyms, and Classification
[198]
Douros A, Cui Y, Dell'Aniello S et al.. “Influenza Immunization at Midlife and the Risk of Parkinson Disease.” JAMA network open (2025). PMID: 41348356 ↗
L3bCited in: Definition, Synonyms, and Classification
[199]
Chernicky J, Dworetsky A, Grossen S et al.. “Towards precision functional brain network mapping in Parkinson's disease.” NeuroImage. Clinical (2025). PMID: 41496387 ↗
L3bCited in: Definition, Synonyms, and Classification
[200]
Simuni T, Gochanour C, Nair AR et al.. “Neuronal α-Synuclein Disease Stage Progression over 5 Years.” Movement disorders : official journal of the Movement Disorder Society (2025). PMID: 40302527 ↗
L3bCited in: Definition, Synonyms, and Classification
[201]
Zülke AE, Luppa M, Sander C et al.. “Prevalence and associated factors of subjective cognitive decline (SCD Plus): a cross-sectional analysis of three population-based European cohorts.” Alzheimer's research & therapy (2026). PMID: 42174744 ↗
L3bCited in: Definition, Synonyms, and Classification
[202]
Liu Y, Chen M, Chen P et al.. “Machine learning-based stratification of mild cognitive impairment in Parkinson's disease: a multicenter cross-sectional analysis.” BMC medical informatics and decision making (2025). PMID: 41094519 ↗
L3bCited in: Definition, Synonyms, and Classification
[203]
Croteau D, Tobenkin A, Chan V et al.. “Corneal edema: an underrecognized safety risk of amantadine.” Journal of neurology (2026). PMID: 42000941 ↗
L4Cited in: Definition, Synonyms, and Classification
[204]
Sarasso E, Pelosin E, Ruotolo I et al.. “Exploring the fatigue phenomenon in individuals with Parkinson's disease: an Italian multicenter cross-sectional study.” Acta neurologica Belgica (2026). PMID: 42065803 ↗
L3bCited in: Definition, Synonyms, and Classification
[205]
Battaglion GGS, Boni FDS, Zhang K et al.. “Virtual Reality and Body Weight-Supported Treadmill Training in Gait Rehabilitation for Parkinson Disease: A Systematic Review.” American journal of physical medicine & rehabilitation (2026). PMID: 41811930 ↗
L1aCited in: Supportive Care and Complication Management
[206]
Kloster CT, Bonde-Jensen F, Langeskov-Christensen M et al.. “Parkinson's Disease and Voluntary Walking Interventions-A Systematic Review and Meta-analysis.” Archives of physical medicine and rehabilitation (2026). PMID: 41628826 ↗
L1aCited in: Supportive Care and Complication Management
[207]
Ellis T. “Movement Through Time: The Evolution of Treatment for People With Parkinson Disease.” Journal of neurologic physical therapy : JNPT (2026). PMID: 42313921 ↗
L1bCited in: Supportive Care and Complication Management
[208]
Bosch-Barceló P, Tersa-Miralles C, Martínez-Navarro O et al.. “A treadmill training program in a gamified virtual reality environment combined with transcranial direct current stimulation in Parkinson's Disease: Preliminary results of a mixed methods randomized controlled trial.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42277373 ↗
L4Cited in: Supportive Care and Complication Management
[209]
Zhang HY, Hou TT, Chen KK et al.. “Intermittent theta-burst stimulation to enhance physical therapy in Parkinson's disease: The STEP-PD randomized trial.” Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2026). PMID: 41926908 ↗
L1bCited in: Supportive Care and Complication Management
[210]
Lim S, Park J, Kim J et al.. “Clinical efficacy of a non-immersive virtual reality-based balance training device in improving balance and gait in Parkinson's disease; A randomized controlled trial.” Parkinsonism & related disorders (2026). PMID: 41855753 ↗
L1bCited in: Supportive Care and Complication Management
[211]
Yilmaz S, Aslam S, Sillau S et al.. “Bridging the gap: Evaluating a community-based palliative care intervention for underserved patients with Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41812391 ↗
L1bCited in: Supportive Care and Complication Management
[212]
Skelly R, Lindop F, Gordon AL et al.. “Telerehabilitation for early-stage Parkinson's disease: A randomized controlled feasibility trial of individualised real-time physiotherapy delivered via a videoconference platform.” Journal of Parkinson's disease (2026). PMID: 41719152 ↗
L4Cited in: Supportive Care and Complication Management
[213]
Alegre-Tamariz J, Ramirez C, Runzer-Colmenares FM et al.. “Effects of a gait training program with the Fisior® sequential square mat on balance and gait in patients with Parkinson's disease: a randomized clinical trial.” BMC complementary medicine and therapies (2026). PMID: 41555326 ↗
L1bCited in: Supportive Care and Complication Management
[214]
Garcez PA, DeJesus BM, Oliveira LR et al.. “Effect of transcutaneous electrical nerve stimulation associated to exercise for pain in Parkinson's disease: a randomized crossover clinical trial.” Pain management (2026). PMID: 42083446 ↗
L1bCited in: Supportive Care and Complication Management
[215]
Karabacak A, Gezer Karabacak T, Özen Barut B. “Efficacy of Suprascapular Nerve Block and Pulsed Radiofrequency for Chronic Shoulder Pain in Parkinson's Disease.” Pain research & management (2026). PMID: 42213538 ↗
L2bCited in: Supportive Care and Complication Management
[216]
Shaikh AG, Antoniades C, Arshad Q et al.. “Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.” Current opinion in neurology (2026). PMID: 42307076 ↗
L1cCited in: Guidelines and Resources
[217]
Ory Magne F, Drapier S, Marques AR et al.. “A delphi consensus statement about French practical management of continuous apomorphine infusion in patients with Parkinson's disease and motor fluctuations.” Parkinsonism & related disorders (2025). PMID: 40413152 ↗
L1cCited in: Guidelines and Resources
[218]
Buhmann C, Kalbe E, Claus I et al.. “Parkinson´s day-clinic: which patients should be selected and what services should be offered for successful therapy?” Journal of neural transmission (Vienna, Austria : 1996) (2025). PMID: 40299066 ↗
L1cCited in: Guidelines and Resources
[219]
Rodrigues AM, Costa C, Gago M et al.. “Expert perspectives on the use of safinamide for Parkinson's disease in Portugal: insights from a Portuguese Delphi Consensus.” Journal of comparative effectiveness research (2025). PMID: 40474741 ↗
L1cCited in: Guidelines and Resources
[220]
Popławska-Domaszewicz K, Siuda J, Rudzińska-Bar M et al.. “Challenges of equitable access to device-aided therapies for advanced Parkinson's Disease in Poland - expert consensus and treatment recommendations.” Neurologia i neurochirurgia polska (2024). PMID: 39737586 ↗
L1cCited in: Guidelines and Resources
[221]
Xu J, Xu X, Guo X et al.. “Improving reliability of movement assessment in Parkinson's disease using computer vision-based automated severity estimation.” Journal of Parkinson's disease (2025). PMID: 39973505 ↗
L2bCited in: Guidelines and Resources
[222]
Trundell D, Davies EW, Barrett L et al.. “Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III.” Journal of Parkinson's disease (2025). PMID: 39973477 ↗
L2bCited in: Guidelines and Resources